[go: up one dir, main page]

EP2051978A2 - Dérivés d'acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur - Google Patents

Dérivés d'acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur

Info

Publication number
EP2051978A2
EP2051978A2 EP07809149A EP07809149A EP2051978A2 EP 2051978 A2 EP2051978 A2 EP 2051978A2 EP 07809149 A EP07809149 A EP 07809149A EP 07809149 A EP07809149 A EP 07809149A EP 2051978 A2 EP2051978 A2 EP 2051978A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
methyl
pyrazol
acetamide
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07809149A
Other languages
German (de)
English (en)
Inventor
Bradley Teegarden
Konrad Feichtinger
Sonja Strah-Pleynet
Brett Ullman
Yifeng Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of EP2051978A2 publication Critical patent/EP2051978A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor.
  • Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
  • the present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.
  • G Protein coupled receptors share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane. The transmembrane helices are joined by strands of amino acids having a larger loop between the fourth and fifth transmembrane helix on the extracellular side of the membrane. Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The carboxy terminus of the receptor lies intracellularly with the amino terminus in the extracellular space. It is thought that the loop joining helices five and six, as well as, the carboxy terminus, interact with the G protein. Currently, Gq, Gs, Gi and Go are G proteins that have been identified.
  • G protein coupled receptors exist in the cell membrane in equilibrium between two different states or conformations: an "inactive" state and an “active” state.
  • a receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response.
  • Changing the receptor conformation to the active state allows linkage to the transduction pathway and produces a biological response.
  • a receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand.
  • Recent discoveries such as, including but not exclusively limited to, modifications to the amino acid sequence of the receptor provide means other than ligands to stabilize the active state conformation. These means effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent means is termed "constitutive receptor activation.”
  • Serotonin (5-hydroxytryptamine, 5-HT) are an important class of G protein coupled receptors. Serotonin is thought to play a role in processes related to learning and memory, sleep, thermoregulation, mood, motor activity, pain, sexual and aggressive behaviors, appetite, neurodegenerative regulation, and biological rhythms. Not surprisingly, serotonin is linked to pathophysiological conditions such as anxiety, depression, obsessive compulsive disorders, schizophrenia, suicide, autism, migraine, emesis, alcoholism, and neurodegenerative disorders.
  • these types of therapeutics can generally be divided into two classes, the "typical” and the “atypical.” Both have anti-psychotic effects, but the typicals also include concomitant motor-related side effects (extra pyramidal syndromes, e.g., lip-smacking, tongue darting, locomotor movement, etc). Such side effects are thought to be associated with the compounds interacting with other receptors, such as the human dopamine D 2 receptor in the nigro-striatal pathway. Therefore, an atypical treatment is preferred. Haloperidol is considered a typical anti-psychotic, and clozapine is considered an atypical anti-psychotic. Serotonin receptors are divided into seven subfamilies, referred to as 5-HTi through 5-
  • HT 7 inclusive. These subfamilies are further divided into subtypes.
  • the 5-HT 2 subfamily is divided into three receptor subtypes: 5-HT 2A , 5-HT 2B , and 5-HT 2C -
  • the human 5- HT 2C receptor was first isolated and cloned in 1987, and the human 5-HT 2A receptor was first isolated and cloned in 1990. These two receptors are thought to be the site of action of hallucinogenic drugs.
  • antagonists to the 5-HT 2A and 5-HT 2C receptors are believed to be useful in treating depression, anxiety, psychosis, and eating disorders.
  • U.S. Patent Number 4,985,352 describes the isolation, characterization, and expression of a functional cDNA clone encoding the entire human 5-HT lc receptor (now known as the 5- HT 2C receptor).
  • U.S. Patent Numbers 5,661,024 and 6,541,209 describe the isolation, characterization, and expression of a functional cDNA clone encoding the entire human 5-HT 2A receptor.
  • Casey describes a mutation of the cysteine residue at position which reportedly led to constitutive activation.
  • Herrick-Davis 1 and Herrick-Davis 2 describe mutations of the serine residue at position 312 of the rat 5-HT 2 c receptor to phenylalanine (S312F) and lysine (S312K), which reportedly led to constitutive activation.
  • One aspect of the present invention pertains to certain compounds as shown in Formula (Ia):
  • V is O or NH
  • W is C M alkylene optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 substituents selected independently from the group consisting OfC] -3 alkyl, Q _ 4 alkoxy, carboxy, cyano, C 3-7 cycloalkyl, Ci -3 haloalkyl, halogen, and oxo, or W is absent;
  • Z is -NR 10 R 11 , -NR !0 -( X )-R n , -OR 11 , -O-( X )-R n ; -SR 11 , -S-( X )-R 11 , -S(O)R 11 ,
  • X is C M alkylene optionally substituted with I 5 2, 3, 4, 5, 6, 7, or 8 substituents selected independently from the group consisting Of C 1-3 alkyl, Ci- 4 alkoxy, carboxy, cyano, Q -3 haloalkyl, halogen and oxo;
  • R 1 is selected from the group consisting of H, Ci-S alkyl, C 2-6 alkenyl, C 2-6 alkynyl and C 3-7 cycloalkyl;
  • R 2 is selected from the group consisting of H, Ci -6 acyl, Ci -6 acyloxy, C 2-6 alkenyl, Ci-6 alkoxy, Ci -6 alkyl, Ci -6 alkylcarboxamide, C 2-6 alkynyl, Ci -6 alkylsulfonamide, Ci -6 alkylsulfinyl, Ci -6 alkylsulfonyl, Ci -6 alkylthio, Ci -6 alkylureyl, amino, C ⁇ e alkylamino, C 2-8 dialkylamino, carbo-Ci_ 6 -alkoxy, carboxamide, carboxy, cyano, C 3 J 7 cycloalkyl, C 2-8 dialkylcarboxamide, C 2-S dialkylsulfonamide, halogen, Ci -6 haloalkoxy, Q -6 haloalkyl, C )-6 haloalkylsulf ⁇ nyl, Ci -6 haloalkylsul
  • R 3 is selected from the group consisting of H, C 2-6 alkenyl, Ci -6 alkoxy, Ci -6 alkyl, Ci -6 alkylcarboxamide, C 2 .g alkynyl, C 1 . 6 alkylsulfonamide, carbo-C l-6 -alkoxy, carboxamide, carboxy, cyano, C 3-7 cycloalkyl, C 2-8 dialkylcarboxamide, halogen, heteroaryl and phenyl; and wherein each of said C 2-6 alkenyl, Ci -6 alkyl, C 2-6 alkynyl, Ci -6 alkylsulfonamide, C 3-7 cycloalkyl, heteroaryl and phenyl groups are optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Ci -5 acyl, Q -5 acyloxy, C 2-6 alkenyl, Ci -4 alkoxy, Ci -8 alkyl, Ci -6 alkylamin
  • R 4 is H, amino, Ci -6 alkylamino, C 2-8 dialkylaxnino, heterobicyclic, heterocyclyl, or heteroaryl, wherein said amino, Ci -6 alkylamino, C 2- S dialkylamino, heterobicyclic, heterocyclyl, and heteroaryl are each optionally substituted with 1 , 2, 3, 4, or 5 substituents selected independently from the group consisting of Ci -6 acyl, Ci -I2 acyloxy, C 2-6 alkenyl, Ci -4 alkoxy, C x .
  • R 5 , R 6 and R 7 are each selected independently from the group consisting of H, C 1-6 acyl, Ci -6 acyloxy, C 2-6 alkenyl, Ci -6 alkoxy, Ci -6 alkyl, Ci -6 alkylcarboxamide, C 2-6 alkynyl, Ci -6 alkylsulfonamide, Ci -6 alkylsulfinyl, Cj. 6 alkylsulfonyl, Ci. 6 alkylthio, Cj -6 alkylureyl, amino, Ci-
  • R 8 and R 9 are each selected independently from the group consisting of H 3 Ci.j alkyl, Ci- 4 alkoxy, carboxy, cyano, Cu haloalkyl, and halogen, or
  • R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl or C 3- 7 cycloalkyl group
  • R 10 is H or C, -5 -alkyl; and R ⁇ is H, Ci -8 -alkyl, aryl, C 3-I0 cycloalkyl, heteroaryl, or heterocyclyl each optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Ci -6 acyl, C 1-6 acyloxy, C 2-6 alkenyl, Ci -6 alkoxy, C !-6 alkyl, Ci -6 alkylcarboxamide, C 2-6 alkynyl, Cue alkylsulfonamide, Ci -6 alkylsulfinyl, Ci -6 alkylsulfonyl, Ci.6 alkylthio, Cj -6 alkylureyl, amino, Ci -6 alkylamino, C 2- s dialkylamino, Ci- ⁇ alkylimino, carbo-Ci -6 -alkoxy, carboxamide, carboxy, cyano, C3-7 cycloalky
  • R 10 and R ⁇ together with the nitrogen to which they are both bonded form a heterocyclyl group or a heteroaryl group each optionally substituted with Ci. 6 -alkyl, aryl, heteroaryl, aryl-Ci -3 -alkyl, or heteroaryl -Cu 3 -alkyl, wherein said Q-e-alkyl, aryl, heteroaryl, aryl-Q -3 -alkyl, and heteroaryl-C 1-3 -alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting OfCi -6 acyl, C 1-6 acyloxy, C 2-6 alkenyl, C 1-6 alkoxy, Cj.
  • One aspect of the present invention encompasses pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • One aspect of the present invention pertains to methods for modulating the activity of a
  • 5-HT 2A serotonin receptor by contacting the receptor with a compound according to any of the embodiments described herein or a pharmaceutical composition thereof.
  • One aspect of the present invention pertains to methods for treating a 5-HT 2A associated disorder in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition thereof.
  • One aspect of the present invention pertains to processes for preparing a composition comprising admixing a compound according to any of the embodiments described herein and a pharmaceutically acceptable carrier.
  • One aspect of the present invention pertains to the use of a compound of the present invention for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder.
  • One aspect of the present invention pertains to compounds according to any of the embodiments described herein for use in a method of treatment of the human or animal body by therapy.
  • One aspect of the present invention pertains to compounds according to any of the embodiments described herein for use in a method for the treatment of a 5-HT 2A associated disorder, as described herein, in the human or animal body by therapy.
  • Figure 1 shows the general synthetic scheme for the preparation of intermediate compounds of the present invention.
  • Figure 1 shows a general coupling method between a pyrazole boronic acid and an aryl triflate, it is understood that similar coupling methods known in the art can also be used, and a halide, such as, I, Br or Cl, can be used in place of the triflate.
  • Figure 2 shows the general synthetic scheme for the preparation of intermediate compounds of the present invention wherein "V" is oxygen.
  • Figure 2 shows a general coupling method between a pyrazole boronic acid and a phenyl halide using coupling methods known in the art, such as a Suzuki coupling, and the like.
  • the alkyl amide protecting group can be hydrolyzed to provide the amine intermediate of the present invention.
  • Figure 3 shows the general synthetic scheme for the preparation of intermediate compounds of the present invention.
  • Figure 3 illustrates general methods for introducing a variety of halogens to compounds of the invention. It is understood that these halogenation reactions can also be conducted later in the synthesis, for example as the last step.
  • Figure 4 shows the general synthetic scheme for the preparation of intermediate compounds of the' present invention.
  • Figure 4 shows the general reactions, such as, alkylation and Mitsunobu-like reactions, for introducing the -W-R 4 group.
  • Figure 5 shows the general synthetic scheme for the preparation of compounds of the present invention.
  • Figure 5 shows the general coupling reactions of the amino-intermediate with carboxylic acids, acyl halides, and the like.
  • Figure 6 shows the general synthetic scheme for the preparation of intermediates and compounds of the present invention.
  • Figure 6 illustrates the general methods for preparing pyrazoles of the present invention using substituted and unsubstituted hydrazines.
  • Figure 7 shows the general synthetic scheme for the preparation of compounds of the present invention wherein the -W-R 4 group is introduced in the last ste ⁇ (s).
  • Figure 7 shows the general reactions, such as, alkylation and Mitsunobu-like reactions, for introducing the -W-R 4 group.
  • Figure 8 shows the general synthetic scheme for the preparation of compounds of the invention wherein V is NH in Formula (Ia) and the -W-R 4 group is introduced in the last step(s).
  • Figure 8 shows the general reactions, such as, alkylation reactions, for introducing the -W-R 4 group wherein V is NH.
  • Figure 9 shows the general synthetic scheme for the preparation of intermediates and compounds of the present invention.
  • Figure 9 illustrates the coupling of the a carboxylic acid containing an as-leaving group (LG) and subsequent displacement with an alcohol, amine or thiol to provide compounds of Formula (Ia) wherein Z is -NR 10 R 11 , -NR 10 -( X )-R H , -OR 11 , -O-( X )-R n ; -SR 1 ', and -S-( X )-R u .
  • LG as-leaving group
  • Figure 9 also illustrates the oxidation of thioethers into compounds of Formula (Ia) wherein Z is -S(O)R 1 ', -S(O)-( X )-R", -S(O) 2 R 11 , and -S(O) 2 -( X )-R 11 .
  • agonists shall mean moieties that interact and activate the receptor, such as the
  • 5-HT 2A receptor initiates a physiological or pharmacological response characteristic of that receptor. For example, when moieties activate the intracellular response upon binding to the receptor, or enhance GTP binding to membranes.
  • antagonist is intended to mean moieties that competitively bind to the receptor at the same site as agonists (for example, the endogenous ligand), but which do not activate the intracellular response initiated by the active form of the receptor, and can thereby inhibit the intracellular responses by agonists or partial agonists. Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
  • contact or contacting is intended to mean bringing the indicated moieties together, whether in an in vitro system or an in vivo system.
  • "contacting" a 5HT 2A receptor with a compound of the invention includes the administration of a compound of the present invention to an individual, preferably a human, having a 5HT 2A receptor, as well as, for example, introducing a compound of the invention into a sample containing a cellular or more purified preparation containing a 5HT 2A receptor.
  • in need of treatment is intended to mean a judgment made by a caregiver
  • the compounds of the invention can be used in a protective or preventive manner; or compounds of the invention can be used to alleviate, inhibit or ameliorate the disease, condition or disorder.
  • the term "individual” is intended to mean any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • inverse agonists is intended to mean moieties that bind the endogenous form of the receptor or to the constitutively activated form of the receptor, and which inhibit the baseline intracellular response initiated by the active form of the receptor below the normal base level of activity which is observed in the absence of agonists or partial agonists, or decrease GTP binding to membranes.
  • the baseline intracellular response is inhibited in the presence of the inverse agonist by at least 30%, more preferably by at least 50%, and most preferably by at least 75%, as compared with the baseline response in the absence of the inverse agonist.
  • isolated refers to material that is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a metabolite that is formed from a parent compound present in a natural system e.g. individual
  • the same metabolite, separated from some or all of the coexisting materials in the natural system is considered isolated.
  • the metabolite that is prepared by synthetic means is also considered isolated.
  • modulate or modulating is intended to mean an increase or decrease in the amount, quality, response or effect of a particular activity, function or molecule.
  • pharmaceutical composition is intended to mean a composition comprising at least one active ingredient; including but not limited to, salts, solvates and hydrates of compounds of Formula (Ia); whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human).
  • a mammal for example, without limitation, a human.
  • terapéuticaally effective amount is intended to mean the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following: (1) Preventing the disease; for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease, (2) Inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), and (3) Ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
  • CHEMICAL GROUP MOIETY OR RADICAL: The term directly preceeding the chemical group beginning with "C” followed directly by a subscript number or a subscript range of numbers refers to the number of carbons associated with the chemical group.
  • Ci- ⁇ in the chemical group “Ci_ 6 alkyl” refers to an alkyl group containing one, two, three, four, five, or six carbons, and all possible isomers.
  • Ci -12 acyl denotes a C 1-I2 alkyl radical attached to a carbonyl wherein alkyl has the same definition as described herein, some embodiments are when acyl is C 1-6 acyl, some embodiments are when acyl is Ci -S acyl; some examples include, but are not limited to, acetyl, propionyl, n-butanoyl, iso-butanoyl, sec-butanoyl, f-butanoyl (i.e., pivaloyl), pentanoyl and the like.
  • C 1- J 2 acyloxy denotes an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some embodiments are when acyloxy is Ci -M acyloxy, some embodiments are when acyloxy is Ci -1 O acyloxy, some embodiments are when acyloxy is C] -8 acyloxy, some embodiments are when acyloxy is Q-s acyloxy, some embodiments are when acyloxy is C 1 .5 acyloxy, some embodiments are when acyloxy is d. 4 acyloxy, some embodiments are when acyloxy is C 10 . 12 acyloxy, some embodiments are when acyloxy is C S .
  • 1O acyloxy examples include, but are not limited to, acetyloxy, propionyloxy, butanoyloxy, tso-butanoyloxy, sec-butanoyloxy, /-butanoyloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, octanoyloxy, nonanoyloxy, decanoyloxy, undecanoyloxy, dodecanoyloxy, and the like.
  • C 2-6 alkenyl denotes a radical containing 2 to 6 carbons wherein at least one carbon-carbon double bond is present, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons. Both E and Z isomers are embraced by the term “alkenyl.” Furthermore, the term “alkenyl” includes di- and tri- alkenyls. Accordingly, if more than one double bond is present then the bonds may be all E or Z or a mixtures of E and Z.
  • alkenyl examples include vinyl, allyl, 2-butenyl, 3-butenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexanyl, 2,4-hexadienyl and the like.
  • C 1 ⁇ alkoxy denotes an alkyl radical, as defined herein, attached directly to an oxygen atom. Examples include methoxy, ethoxy, n-propoxy, iso- propoxy, ⁇ -butoxy, t-butoxy, ir ⁇ -butoxy, .sec-butoxy and the like.
  • Ci -6 alkyl has the same definition as found herein.
  • Examples of Ci -6 alkoxycarbonylamino include methoxycarbonylamino, ethoxycarbonylamino, isopropoxycarbonylamino, propoxycarbonylamino, tert-butoxycarbonylamino, butoxycarbonylamino, and the like.
  • the term "Cj_ 8 alkyl” denotes a straight or branched carbon radical containing 1 to 8 carbons, some embodiments are 1 to 6 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons, and some embodiments are 1 or 2 carbons.
  • alkyl examples include, but are not limited to, methyl, ethyl, «-propyl, i ⁇ -propyl, n-butyl, sec-butyl, iso- butyl, /-butyl, pentyl, iso-pentyl, t-pentyl, neo-pentyl, 1-methylbutyl [i.e., -CH(CH 3 )CH 2 CH 2 CH 3 ], 2-methylbutyl [i.e., -CH 2 CH(CH 3 )CH 2 CH 3 ], n-hexyl and the like.
  • Ci -6 alkylcarboxamido or "Cj -6 alkylcarboxamide” denotes a single Ci -6 alkyl group attached to the nitrogen of an amide group, wherein alkyl has the same definition as found herein.
  • the Ci -6 alkylcarboxamido may be represented by the following:
  • Examples include, but are not limited to, N-methylcarboxamide, N-ethylcarboxamide, N-n- propylcarboxamide, JV- wo-propylcarboxamide, N-n-butylcarboxamide, N-sec- butylcarboxamide, N- wo-butylcarboxamide, iV-f-butylcarboxamide and the like.
  • C 1 - 4 alkylene refers to a C] -4 divalent straight carbon group containing 1 to 4 carbons, some embodiments are 1 to 3 ca ⁇ bons, some embodiments are 1 to 2 carbons.
  • alkylene refers to, for example, -CHz-, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and the like.
  • Ci -6 alkylsulfinyl denotes a Ci -6 alkyl radical attached to a sulfoxide radical of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfinyl, ethylsulfmyl, ra-propylsulfinyl, iso- propylsulfmyl, n-butylsulfinyl, .sec-butylsulf ⁇ nyl, iso-butylsulfinyl, t-butylsulf ⁇ nyl, and the like.
  • Ci -6 alkylsulfonamide refers to the groups shown below: wherein Ci. 6 alkyl has the same definition as described herein.
  • Ci- ⁇ alkylsulfonyl denotes a Q. 6 alkyl radical attached to a sulfone radical of the formula: -S(O)2- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, «-propylsulfonyl, iso- propylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, is ⁇ -butylsulfonyl, /-butylsulfonyl, and the like.
  • Ci- ⁇ alkylthio denotes a Ci -6 alkyl radical attached to a sulfide of the formula: -S- wherein the alkyl radical has the same definition as described herein. Examples include, but are not limited to, methylsulfanyl (i.e., CH 3 S-), ethylsulfanyl, w-propylsulfanyl, iso- propylsulfanyl, n-butylsulfanyl, sec-butylsulfanyl, iso-butylsulfanyl, .-butylsulfanyl, and the like.
  • Ci- ⁇ alkylthiocarboxam.de denotes a thioamide of the following formulae:
  • Ci -4 alkyl has the same definition as described herein.
  • Ci- ⁇ alkylureyl denotes the group of the formula: -NC(O)N- wherein one or both of the nitrogens are substituted with the same or different Ci -6 alkyl group wherein alkyl has the same definition as described herein.
  • alkylureyl include, but are not limited to, CH 3 NHC(O)NH-, NH 2 C(O)NCH 3 -, (CH 3 ) 2 NC(O)NH-, (CH 3 ) 2 NC(O)NH-, (CHs) 2 NC(O)NCH 3 -, CH 3 CH 2 NHC(O)NH-, CH 3 CH 2 NHC(O)NCH 3 -, and the like.
  • C 2 -6 alkynyl denotes a radical containing 2 to 6 carbons and at least one carbon-carbon triple bond, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons.
  • alkynyl examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2- pentynyl, 3- ⁇ entynyl, 4-pentynyl, 1-hexynyl, 2-hexynyI, 3-hexynyl, 4-hexynyl, 5-hexynyl and the like.
  • alkynyl includes di- and tri-ynes.
  • amino denotes the group -NH 2 .
  • Cj -6 alkylamino denotes one alkyl radical attached to an amino radical wherein the alkyl radical has the same meaning as described herein. Some examples include, but are not limited to, methylamino, ethylamino, jj-propylamino, fso-propylamino, n- butylamino, ⁇ ec-butylamino, jjo-butylamino, /-butylamino, and the like. Some embodiments are "Ci -2 alkylamino.”
  • aryl denotes a 6- to 12-membered mono- or bicyclic ring system containing only ring carbons wherein at least one ring is aromatic. Examples include phenyl, 1,2,3,4- tetrahydro-naphthalen-1 -yl, l,2,3,4-tetrahydro-naphthalen-2-yl, 5,6/7,8-tetrahydro-naphthalen- 1-yl, 5,6,7,8-tetrahydro-naphthalen-2-yl, indan-4-yl, naphtha-1-yl, naphtha-2-yl, and the like.
  • arylalkyl defines a C r C 4 alkylene, such as -CH 2 -, -CH 2 CH 2 - and the like, which is further substituted with an aryl group.
  • Examples of an “arylalkyl” include benzyl, phenethylene and the like.
  • arylcarboxamido denotes a single aryl group attached to the nitrogen of an amide group, wherein aryl has the same definition as found herein.
  • the example is N- phenylcarboxamide.
  • arylureyl denotes the group -NC(O)N- where one of the nitrogens are substituted with an aryl.
  • benzyl denotes the group -CH 2 C 6 H 5 .
  • bicyclic refers to two Gj -7 cyclalkyl groups that share two ring carbons thus forming either a fused or bridged ring.
  • Bicyclic examples include, but not limited to, bicyclo[l.l.l]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.1.l]heptyl, bicyclo[3.2.1]octyl, and the like.
  • carbo-d-e-alkoxy refers to a Cj -6 alkyl ester of a carboxylic acid, wherein the alkyl group is as defined herein. Examples include, but are not limited to, carbomethoxy, carboethoxy, carbopropoxy, carboisopropoxy, carbobutoxy, carbo-sec-butoxy, carbo-iso-butoxy, carbo-f-butoxy, carbo-n-pentoxy, carbo-iso-pentoxy, carbo-£-pentoxy, carbo-neo-pentoxy, carbo-n-hexyloxy, and the like.
  • carboxylate refers to the group -CONH 2 .
  • carboxy or “carboxyl” denotes the group -CO 2 H; also referred to as a carboxylic acid group.
  • cyano denotes the group -CN.
  • C 4 J 7 cydoalkenyl denotes a non-aromatic ring radical containing 4 to 7 ring carbons and at least one double bond; some embodiments contain 4 to 6 carbons; some embodiments contain 4 to 5 carbons; some embodiments contain 4 carbons. Examples include cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl, and the like.
  • C 3-I0 cycloalkyl denotes a saturated monocyclic, bicyclic, or tricyclic ring radical containing 3 to 8 carbons; some embodiments contain 3 to 7 carbons; some embodiments contain 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 5 to 7 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, bicyclo[2.2.1]heptyl, and the like.
  • Examples of the C 3-7 cycloalkylcarbonyl group include, but not limited to, cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, and the like.
  • C 3 ⁇ cycloalkylene refers to a divalent cycloalkyl radical, where cycloalkyl is as defined herein, containing 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons.
  • the C 3 . 6 cycloalkylene group has the two bonding groups on the same ring carbon, for example:
  • the C 3 _ 6 cycloalkylene group has the two bonding groups on different ring carbons. It is understood that "when the two groups of the C 3-6 cycloalkylene group are on different ring carbons they may be cis or trans or mixtures thereof with respect to each other.
  • C 2-8 dialkylamino denotes an amino substituted with two of the same or different C 1-4 alkyl radicals wherein alkyl radical has the same definition as described herein.
  • Cz ⁇ dialkylamino The term “C 2-8 dialkylcarboxamido” or “C z-S dialkylcarboxamide”denotes two alkyl radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein.
  • a C 2 .$ dialkylcarboxamido may be represented by the following groups:
  • Ci -4 has t same definition as described herein.
  • dialkylcarboxamide examples include, but are not limited to, N,N-dirnethylcarboxamide, N-methyl-N-ethylcarboxamide, N,N- diethylcarboxamide, N-methyl-N-isopropylcarboxamide, and the like.
  • C 2-8 dialkylsulfonamide refers to one of the following groups shown below:
  • C 1-4 has the same definition as described herein, for example but are not limited to, methyl, ethyl, w-propyl, isopropyl, and the like.
  • C 2-8 dialkylthiocarboxamido or "C 2-8 dialkylthiocarbox-amide”denotes two alkyl radicals, that are the same or different, attached to a thioamide group, wherein alkyl has the same definition as described herein.
  • a C 2-8 dialkylthiocarboxamido or C 2-B dialkylthiocarboxamide may be represented by the following groups:
  • dialkylthiocarboxamide examples include, but are not limited to, N//- dimethylthiocarboxamide, N-methyl-N-ethylthiocarboxamide and the like.
  • C t ⁇ haloalkoxy denotes a Cj.6 haloalkyl, as defined herein, which is directly attached to an oxygen atom. Examples include, but are not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy and the like.
  • d.6 haloalkyl denotes an Ci.6 alkyl group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted and a fully substituted C
  • haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl., trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl and the like.
  • the term "Ci -6 haloalkylcarboxamide” denotes an C 1-6 alkylcarboxamide group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula C n L 2n+! wherein L is a halogen and "n" is 1, 2, 3, 4, 5 or 6.
  • Cj -6 haloalkylsulf ⁇ nyl denotes a C )-6 haloalkyl radical attached to a sulfoxide group of the formula: -S(O)- wherein the haloalkyl radical has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulfinyl, 2,2,2- trifluoroethylsulf ⁇ nyl, 2,2-difluoroethylsulfinyl and the like.
  • Ci_ « haloalkylsulfonyl denotes a Ci -6 haloalkyl radical attached to a sulfone group of the formula: -S(O) 2 - wherein haloalkyl has the same definition as described herein. Examples include, but are not limited to, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2-difluoroethylsulfonyl and the like.
  • Q -6 haloalkylthio denotes a C 1-6 haloalkyl radical directly attached to a sulft ⁇ r wherein the haloalkyl has the same meaning as described herein. Examples include, but are not limited to, trifluoromethylthio (i.e., CF 3 S-, also referred to as trifluoromethylsulfanyl),
  • halogen or halo denotes to a fluoro, chloro, bromo or iodo group.
  • heteroaryl denotes a 6- to 12-membered mono- or bicyclic ring system wherein at least one ring atom is a heteroatom and at least one ring is aromatic. Examples of a heteroatom include, O, S, ⁇ and the like. In some embodiments, ⁇ is optionally substituted, for example, H, or Ci_ 4 alkyl.
  • heteroaryl groups include, but are not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinolinyl, benzoxazolyl, benzothiazolyl, lH-benzimidazolyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pyrrolyl, indolyl, l ⁇ f-benzoimidazol-2-yl, benzo[l,3]dioxoI-5-yI, 3,4-dihydro-2 ⁇ -benzo[l,4]oxazin-7-yl, 2,3- dihydro-benzofurn-7-yl, 2,3-dihydrb-indoI-l -yl, and the like. Other examples include, but are not limited to, those in TABLE 1, TABLE 2, and the like.
  • heterobicyclic group include, but are not limited to, 2,5-diaza-bicyclo[2.2.1]hept-2-yl, 7-aza- bicyclo[2.2.1]hept-7-yl, and the like.
  • heterocyclic denotes a 3- to 12-menibered mono- or bicyclic non-aromatic ring system wherein at least one ring atom is a heteroatom.
  • the heterocyclic group can be bonded at any available ring atom, for example, ring carbon, ring nitrogen, and the like.
  • the heterocyclic group is a 3-, 4-, 5-, 6- or 7-membered containing ring.
  • Examples of a heterocyclic group include, but are not limited to, aziridin-1-yl, aziridin-2-yl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, piperzin-1-yl, ⁇ i ⁇ erzin-2-yl, piperzin-3-yl, piperzin-4-yl, pyrrolidin-1-yl, ⁇ yrrolidin-2-yl, pyrrolidin-3-yl, [l,3
  • hydroxyl refers to the group -OH.
  • nitro refers to the group -NO 2 .
  • phenoxy refers to the group C 6 HsO-.
  • phenyl refers to the group CgH 5 -.
  • One aspect of the present invention pertains to certain compounds as shown in Formula (Ia):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , V, W, and Z have the same definitions as described herein, supra and infra.
  • the present invention pertains to compounds of Formula (Ia), as described herein, that are isolated. In some embodiments, the present invention pertains to compounds of Formula (Ia), as described herein, that are isolated outside the body of an individual.
  • isolated compounds of Formula (Ia) have a purity of greater than about 0.1%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 99%.
  • the present invention pertains to compounds of Formula (Ia), as described herein, or a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof.
  • substituted indicates that at least one hydrogen atom of the chemical group is replaced by a non-hydrogen substituent or group, the non-hydrogen substituent or group can be monovalent or divalent. When the substituent or group is divalent, then it is understood that this group is further substituted with another substituent or group.
  • a chemical group herein when a chemical group herein is "substituted" it may have up to the full valance of substitution; for example, a methyl group can be substituted by 1, 2, or 3 substituents, a methylene group can be substituted by 1 or 2 substituents, a phenyl group can be substituted by 1, 2, 3, 4, or 5 substituents, a naphthyl group can be substituted by 1 , 2, 3, 4, 5, 6, or 7 substituents and the like.
  • substituted with one or more substituents refers to the substitution of a group with one substituent up to the total number of substituents physically allowed by the group. Further, when a group is substituted with more than one group they can be identical or they can be different.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is understood that the various tautomeric forms are within the scope of the compounds of the present invention.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates and/or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • compounds of the present invention may have one or more chiral centers, and therefore can exist as enantiomers and/or diastereomers.
  • the invention is understood to extend to and embrace all such enantiomers, diastereomers and mixtures thereof, including but not limited, to racemates.
  • some embodiments of the present invention pertain to compounds of the present invention that are R enantiomers.
  • some embodiments of the present invention pertain to compounds of the present invention that are S enantiomers.
  • some embodiments of the present invention include compounds that are RS or SR enantiomers.
  • compounds of the present invention are RR or SS enantiomers. It is understood that compounds of the present invention are intended to represent all possible individual enantiomers and mixtures thereof just as if each had been individually named with the structure provided, unless stated or shown otherwise.
  • Some embodiments of the present invention pertain to certain compounds as shown in the following Formula (Ic): wherein each variable in Formula (Ic) has the same meaning as described herein, supra and infra.
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Ie):
  • V is O.
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Ig):
  • V is NH
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Ii): wherein each variable in Formula (Ii) has the same meaning as described herein, supra and infra.
  • W is -CH 2 - or -CH 2 CH2- optionally substituted with Cu alkyl.
  • W is -CH 2 -, -CH 2 CH 2 -, or -CH 2 C(CH 3 ) 2 -.
  • W is -CHjCH 2 -.
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Ik):
  • Z is -NR 10 R 11 .
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Im):
  • Z is -NR'°-( X )-R u .
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Io): wherein each variable in Formula (Io) has the same meaning as described herein, supra and infra.
  • Z is -OR 11 .
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Iq):
  • Z is -O-( X )-R n .
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Is):
  • Z is -SR 1 ' .
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Iu): wherein each variable in Formula (Iu) has the same meaning as described herein, supra and infra.
  • Z is -S-( X )-R n .
  • Z is -S(O)R 11 .
  • Z is -S(O)-( X )-R' 1 .
  • Z is -S(O) 2 R".
  • Some embodiments of the present invention pertain to certain compounds as shown in Formula (Iw):
  • Z is -S(O) 2 -( X )-R n .
  • X is C 1-4 alkylene. In some embodiments, X is -CH 2 -, or -CH 2 CH 2 -.
  • R 1 is C 1-6 alkyl.
  • R 1 is -CH 3 .
  • Ri is H.
  • tautomeric forms can also have corresponding nomenclature for each represented tautomer, for example, the pyrazol-3-yl groups in Formula (Io) and Formula (Iq) can be represented by the general chemical names lH-pyrazol-3-yl and 2H-pyrazol-3-yI respectively. Therefore, the present invention includes all tautomers and the various nomenclature designations.
  • R 2 is ⁇ .
  • R 3 is ⁇ , Ci -6 alkoxy, Cj.6 alkyl, or halogen.
  • R 3 is ⁇ , -OCH 3 , -CH 3 , Cl, or Br.
  • R 4 is H. In some embodiments, R 4 is amino.
  • R 4 is heterocyclyl optionally substituted with Ci. 6 acyl.
  • R 4 is morpholin-4-yl, 4-acetyl-piperazin-l-yl, pyrrolidin-1-yl, or piperidin-1-yl.
  • R 5 is H. In some embodiments, R 6 is H.
  • R 7 is H.
  • R 5 , R 6 , and R 7 are each H.
  • R 8 and R 9 are each selected independently from H and Ci -3 alkyl.
  • R 8 and R 9 are each selected independently from H and -CH 3 . In some embodiments, R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl.
  • R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl or C 3 . 7 cycloalkyl group.
  • R 10 is H. In some embodiments, R 10 is Ci ⁇ -alkyl.
  • R 10 is -CH 3 .
  • R 1 ' is H.
  • R 11 is Ci -s -alkyl optionally substituted with carboxy.
  • R 11 is -CH 3 , -CH 2 CH 3 , -C(CH 3 ) 3 , or -CH 2 CO 2 H, In some embodiments, R 11 is aryl optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Ci . 6 acyl, C )-6 alkoxy, Ci -6 alkyl, cyano, halogen, Ci- ⁇ haloalkoxy, and Ci -6 haloalkyl.
  • R u is selected from the group consisting of 3,4-difluoro-phenyl, 4-fluoro-phenyl, 3-methoxy-phenyl, 3,5-difluoro-phenyI, 3-fluoro-phenyl, 2,4-difluoro-phenyI, phenyl, 2-fluoro-phenyl, 4-methoxy-phenyl, 2,5-difiuoro-phenyl, 4-chloro-2-fluoro-phenyl, 4- chloro-phenyl, 4-methoxy-phenyl, 4-methyl-phenyl, 2-methyl-phenyl, 4-trifluoromethyl-phenyl, 4-cyano-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro-phenyl, 3-trifluoromethyl-phenyl, 2- cyano-phenyl, 3-methyl-phenyl, 2-cMoro-phenyl, 2-trifluoromethyl-phenyl, 4-acety
  • R 11 is C 3-I0 cycloalkyl. In some embodiments, R 11 is cyclopropyl.
  • R 11 is heteroaryl optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Cue acyl, C 1-6 alkoxy, Q -6 alkyl, cyano, halogen, Cj -6 haloalkoxy, and Cj -6 haloalkyl.
  • heteroaryl is a 5-membered heteroaryl, for example, a 5- membered heteroaryl as shown in TABLE 1:
  • a imidazolyl ring can be bonded at one of the ring nitrogens (i.e., imidazol-1-yl group) or at one of the ring carbons (i.e., imidazol-2-yl, imidazol-4-yl or imiadazol-5-yl group).
  • heteroaryl is a 6-membered heteroaryl, for example, a 6- membered heteroaryl as shown in TABLE 2: TABLE 2
  • heteroaryl group is bonded at any ring carbon.
  • R ⁇ is pyridin-3-yl, pyridin-2-yl, pyridin-4-yl, or benzo[l ,3]dioxol-5-yl.
  • R 1 ' is heteroeyclyl optionally substituted with C]. 6 alkyl o ⁇ phenyl, wherein said alkyl is optionally substituted with phenyl.
  • R 11 is l-phenyl-piperidin-4-yl, l-benzyl-piperidin-4-yl, or tetrahydro-pyran-4-yl.
  • R 10 and R 11 together with the nitrogen to which they are both bonded form a heteroeyclyl group optionally substituted with aryl, heteroaryl, aryl-Ci -3 -alkyl, or heteroaryl-C I-3 -alkyl, wherein said aryl, heteroaryl, aryl-Ci_ 3 -alkyl, and heteroaryl-Ci -3 -alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Ci-s alkoxy, Ci -6 alkyl, cyano, halogen, and C 1-6 haloalkyl.
  • R 10 and R 1 ' together with the nitrogen to which they are both bonded form a piperazin-lyl or ⁇ iperidin-1-yl group optionally substituted with C] -6 alkyl, aryl, heteroaryl, aryl-Ci -3 -alkyl, or heteroaryl-Ci. 3 -alkyl, wherein said aryl, heteroaryl, aryl-Ci -3 -alkyl, and heteroaryl-Ci -3 -alkyl are each optionally substituted with I, 2, 3, 4, or 5 substituents selected independently from the group consisting of Cj -6 alkoxy, C 1-6 alkyl, cyano, halogen, and C 1 ⁇ haloalkyl.
  • R 10 and R 11 together with the nitrogen to which they are both bonded form a 4-[2-(4-fluoro-phenyV)-ethyl]-piperazin-l-yl, 4-(2-fiuoro-phenyl)-piperazin-l-yl, 4- ⁇ yridin-4-yl-piperazin-l -yl, 4-(4-fluoro-phenyl)-piperazin-l-yl, 4-benzo[l ,3]dioxol-5- ylmethyl-piperazin-1-yl, 4-(2-cyano-phenyl)-piperazin-l-yl, 4-p-tolyl-piperazin-l-yl, 4-methyl- ⁇ iperazin-1 -yl, 4-thiazoI-2-yl-piperazin-l-yl, 4-phenyl-piperazin-l-yl, 4-m-tolyl-piperazin-l-yl, 4-(4-chloro
  • R 10 and R 1 ' together with the nitrogen to which they are both bonded form a heteroaryl group optionally substituted with 1, 2, 3, 4, or 5 substituents selected independently from the group consisting of Q -6 alkoxy, C 1-6 alkyl, cyano, halogen, and Ci -6 haloall ⁇ yl.
  • substituents selected independently from the group consisting of Q -6 alkoxy, C 1-6 alkyl, cyano, halogen, and Ci -6 haloall ⁇ yl.
  • W is -CH 2 - or -CH 2 CH 2 - optionally substituted with Ci -3 alkyl
  • Z is -NR 10 R 11 , -NR 10 -( X )-R", -OR 11 , -O-( X )-R n , -SR 11 , or -S(O) 2 R 11 ;
  • X is -CH 2 - or -CH 2 CH 2 -;
  • R 3 is H, Ci -6 alkoxy, Ci -6 alkyl, or halogen;
  • R 4 is H, amino, or heterocyclyl, wherein said heterocyclyl is optionally substituted with C 1-6 acyl;
  • R 8 and R 9 are each selected independently from H and Ci -3 alkyl, or R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl or C 3- 7 cycloalkyl group;
  • R 10 is H or Ci -6 -alkyl; and R 11 is H, Ci- 8 ⁇ alkyl, aryl, C 3-I0 cycloalkyl, heteroaryl, or heterocyclyl, wherein said Ci -8 - alkyl, aryl, C 3 .i 0 cycloalkyl, heteroaryl, and heterocyclyl are each optionally substituted with substituents selected independently from the group consisting Of C) -6 acyl, Ci -6 alkoxy, Ci -6 alkyl, carboxy, cyano, halogen, Ci. 6 haloalkoxy, and C ]-6 haloalkyl; or
  • R 10 and R 1 ' together with the nitrogen to which they are both bonded form a heterocyclyl group or a heteroaryl group each optionally substituted with aryl, heteroaryl, aryl- Cio-alkyl, or heteroaryl-Ci_ 3 -alkyl., wherein said aryl, heteroaryl, aryl-C
  • Some embodiments of the present invention pertain to certain compounds of Formula (Ha):
  • W is -CH 2 -, -CH 2 CH 2 - or -CH 2 C(CHj) 2 -;
  • Z is -NR 10 R", -NR'°-( X )-R n , -OR 1 ', -O-( X )-R ⁇ , -SR 11 , Or -S(O) 2 R 1 ';
  • X is -CH 2 - or -CH 2 CH 2 -;
  • R 3 is H, -OCH 3 , -CH 3 , Cl, or Br;
  • R 4 is H, amino, morpholin-4-yl, 4-acetyl-piperazin-l-yl, pyrrolidin-1-yl, or piperidin-1- yi;
  • R 8 and R 9 are each selected independently from H and -CH 3 , or R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl or cyclohexyl group;
  • R 10 is H or -CH 3 ;
  • R 11 is selected from the group consisting of H 5 -CH 3 , -CH 2 CH 3 , -C(CH 3 ) 3 , -CH 2 CO 2 H, 3,4-difiuoro- ⁇ henyl, 4-fluoro-phenyl, 3-methoxy-phenyl, 3,5-difiuoro-phenyl, 3-fluoro- ⁇ henyl, 2,4-difluoro-phenyl, phenyl, 2-fluoro-phenyl, 4-methoxy-phenyl, 2,5-difluoro-phenyl, 4-chloro- 2-fluoro-phenyl, 4-chloro-phenyl, 4-methoxy-phenyl, 4-methyl-phenyl, 2-methyl-phenyl, 4- trifluoromethyl-phenyl, 4-cyano-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro- ⁇ henyl, 3- trifluoromethyl-phenyl, 2-cyano-pheny
  • Some embodiments of the present invention pertain to certain compounds of Formula (Ha):
  • W is -CH 2 -, -CH 2 CH 2 - or -CH 2 C(CHs) 2 -;
  • Z is -NR 1 V 1 , -NR 10 -( X )-R' ⁇ -OR 11 , -0-( X )-R 11 , -SR 11 , or -S(O) 2 R 11 ;
  • X is -CH 2 - or -CH 2 CH 2 -;
  • R 3 is H, -OCH 3 , -CH 3 , Cl, or Br;
  • R 4 is H, amino, morpholin-4-yl, 4-acetyl-piperazin-l-yI, pyrrolidin-l-yl, or piperidin-1- yi;
  • R s and R 9 are each selected independently from H and -CH 3 , or R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl or cyclohexyl group;
  • R 10 is H or -CH 3 ;
  • R 11 is selected from the group consisting of 3,4-difluoro-phenyl, 4-fluoro- ⁇ henyl, 3- methoxy-phenyl, 3,5-difluoro-phenyl, 3-fluoro-phenyl, 2,4-difluoro-phenyl, phenyl, 2-fluoro- phenyl, 4-methoxy-phenyl, 2,5-difluoro-phenyl, 4-chloro-2-fluoro-phenyl, 4-chloro- ⁇ henyl, 4- methoxy-phenyl, 4-methyl-phenyl, 2-methyl-phenyl, 4-trifluoromethyl-phenyl, 4-cyano-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro-phenyl, 3 -trifluoromethyl -phenyl, 2-cyano-phenyl, 3- methyl-phenyl, 2-chloro-phenyl, 2-trifluoromethyl-phenyl, 4-acety
  • W is -CH 2 -, -CH 2 CH 2 - or -CH 2 C(CH 3 ) 2 -;
  • Z is -NR 10 R 11 , -NR 10 -( X )-R ⁇ , -OR 11 , or -O-( X )-R u ;
  • X is -CH 2 - or -CH 2 CH 2 -;
  • R 3 is H, -OCH 3 , -CH 3 , Cl, or Br;
  • R 4 is H, amino, morpholin-4-yl, 4-acetyl-piperazin-l-yI, pyrrol idin-1-yl, or piperidin-1-yl;
  • R 8 and R 9 are each selected independently from H and -CH 3 , or
  • R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl
  • R 10 is H or -CH 3 ;
  • R n is pyridin-3-yl, pyridin-2-yl, pyridin-4-yl, or benzo[l,3]dioxol-5-yl.
  • Some embodiments of the present invention pertain to certain compounds of Formula (Ha):
  • W is -CH 2 -, -CH 2 CH 2 - or -CH 2 C(CHa) 2 -;
  • Z is -NR 10 R 11 , -NR 10 -( X )-R", -OR 11 , or -O-( X )-R u ;
  • X is -CH 2 - or -CH 2 CH 2 -;
  • R 3 is H, -OCH 3 , -CH 3 , Cl, or Br;
  • R 4 is H, amino, mor ⁇ holin-4-yl, 4-acetyl-piperazin-l-yl, pyrrolidin-1-yl, or piperidin-1-yl;
  • R 8 and R 9 are each selected independently from H and -CH 3 , or
  • R 8 and R 9 together with the carbon to which they are both bonded form a carbonyl; and R 10 and R n together with the nitrogen to which they are both bonded form a 4-[2-(4- fluoro-phenyl)-ethyl]-piperazin-l-yl, 4-(2-fluoro-phenyl)-piperazin-l -yl, 4-pyridm-4-yl- piperazin- 1 -y 1, 4-(4-fluoro-phenyl)-piperazin- 1 -yl, 4-benzo [ 1 ,3]dioxol-5 -ylmethyl-piperazin- 1 - yl, 4-(2-cyano- ⁇ henyl)-piperazin-l-yl, 4-p-tolyl-piperazin-l-yl, 4-methyl- ⁇ i ⁇ erazm-l-yl, 4- thiazol-2-yl-piperazin-l-yl, 4-phenyl-piperazin-l-y
  • the compounds of the Formula (Ia) of the present invention can be prepared according to the general synthetic schemes in Figures 1 through 9 as well as relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter in the working Examples. Protection and deprotection may be carried out by procedures generally known in the art (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3 rd Edition, 1999 [Wiley]; incorporated herein by reference in its entirity).
  • the present invention also encompasses diastereomers as well as optical isomers, e.g.
  • the compounds disclosed herein are believed to be useful in the treatment of several additional diseases and disorders, and in the amelioration of symptoms thereof. Without limitation, these include the following:
  • Antiplatelet agents are prescribed for a variety of conditions. For example, in coronary artery disease they are used to help prevent myocardial infarction or stroke in patients who are at risk of developing obstructive blood clots (e.g., coronary thrombosis).
  • Ih a myocardial infarction (heart attack)
  • the heart muscle does not receive enough oxygen- rich blood as a result of a blockage in the coronary blood vessels. If taken while an attack is in progress or immediately afterward (preferably within 30 minutes), antiplatelets can reduce the damage to the heart.
  • TIA transient ischemic attack
  • mini-stroke A transient ischemic attack
  • Antiplatelet drugs have been found to be effective in preventing TIAs.
  • Angina is a temporary and often recurring chest pain, pressure or discomfort caused by inadequate oxygen-rich blood flow (ischemia) to some parts of the heart.
  • ischemia oxygen-rich blood flow
  • antiplatelet therapy can reduce the effects of angina and the risk of myocardial infarction.
  • Stroke is an event in which the brain does not receive enough oxygen-rich blood, usually due to blockage of a cerebral blood vessel by a blood clot. In high-risk patients, taking antiplatelets regularly has been found to prevent the formation of blood clots that cause first or second strokes.
  • Angioplasty is a catheter based technique used to open arteries obstructed by a blood clot.
  • antiplatelets can reduce the risk of forming additional blood clots following the procedure(s).
  • Coronary bypass surgery is a surgical procedure in which an artery or vein is taken from elsewhere in the body and grafted to a blocked coronary artery, rerouting blood around the blockage and through the newly attached vessel. After the procedure, antiplatelets can reduce the risk of secondary blood clots. Atrial fibrillation is the most common type of sustained irregular heart rhythm (arrythmia).
  • Atrial fibrillation affects about two million Americans every year. Ih atrial fibrillation, the atria (the heart's upper chambers) rapidly fire electrical signals that cause them to quiver rather than contract normally. The result is an abnormally fast and highly irregular heartbeat. When given after an episode of atrial fibrillation, antiplatelets can reduce the risk of blood clots forming in the heart and traveling to the brain (embolism).
  • 5-HT 2A receptors are expressed on smooth muscle of blood vessels and S-ETT secreted by activated platelets causes vasoconstriction as well as activation of additional platelets during clotting.
  • S-ETT secreted by activated platelets causes vasoconstriction as well as activation of additional platelets during clotting.
  • 5-HT 2A inverse agonist will inhibit platelet aggregation and thus be a potential treatment as an antiplatelet therapy (see Satimura, K, et al., Clin Cardiol 2002 Jan. 25 (l):28-32; and Wilson, H.C et al., Thromb Haemost 1991 Sep 2;66(3):355-60).
  • 5-HT 2A inverse agonists can be used to treat, for example, claudication or peripheral artery disease as well as cardiovascular complications (see Br- Med. J. 298: 424 - 430, 1989), Arterial thrombosis (see, Pawlak, D. et al. Thrombosis Research 90: 259 - 270, 1998), atherosclerosis (see, Hayashi, T. et al. Atherosclerosis 168: 23 — 31, 2003), vasoconstriction, caused by serotonin (see, Fujiwara, T. and Chiba, S. Journal of Cardiovascular Pharmacology
  • 5-HT 2A inverse antagonists can increase circulating adiponectin in patients, suggesting that they would also be useful in protecting patients against indications that are linked to adiponectin, for example, myocardial ischemia reperfusion injury and artherosclerosis (see Nomura, Shosaku, et al. Blood Coagulation and Fibrinolysis 2005, 16, 423-428).
  • the 5-HT 2 A inverse agonists disclosed herein provide beneficial improvement in microcirculation to patients in need of antiplatelet therapy by antagonizing the vasoconstrictive products of the aggregating platelets in, for example and not limited to the indications described above. Accordingly, in some embodiments, the present invention provides methods for reducing platelet aggregation in a patient in need thereof comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
  • the present invention provides methods for treating coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, or a symptom of any of the foregoing in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
  • the present invention provides methods for reducing risk of blood clot formation in an angioplasty or coronary bypass surgery patient, or a patient suffering from atrial fibrillation, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein at a time where such risk exists.
  • One aspect of the present invention provides a therapeutic agent for treating indications associated with the pathophysiology of platelet aggregation used in combination with compounds of the present invention as disclosed herein. Accordingly, compounds of the present invention can be used alone or in combination with other therapeutic agent(s), such as, thromboxane A2 blocker (aspirin and the like), and ADP-mediated platelet aggregation inhibitor (ticlopidine, clopidogrel, and the like) either administered together or separately.
  • thromboxane A2 blocker aspirin and the like
  • ADP-mediated platelet aggregation inhibitor ticlopidine, clopidogrel, and the like
  • 5-HT (5-hydroxytryptamine) has been linked to the pathophysiology of acute asthma (see Cazzola, M. and Matera, M.G., TCPS, 2000, 21, 13; and De Bie, JJ. et al., British J. Pharra, 1998, 124, 857-864).
  • the compounds of the present invention disclosed herein are useful in the treatment of asthma, and the treatment of the symptoms thereof. Accordingly, in some embodiments, the present invention provides methods for treating asthma in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein. In further embodiments, methods are provided for treating a symptom of asthma in a patient in need of the treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein. 3. Agitation
  • Agitation is a wel]-recognized behavioral syndrome with a range of symptoms, including hostility, extreme excitement, poor impulse control, tension and uncooperativeness (See Cohen- Mansfield J, and Billig, N., (1986), Agitated Behaviors in the Elderly. I. A Conceptual Review. J Am Geriatr Soc 34(10): 711-721). Agitation is a common occurrence in the elderly and often associated with dementia such as those caused by Alzheimer's disease, Lewy body, Parkinson's, and Huntington's, which are degenerative diseases of the nervous system and by diseases that affect blood vessels, such as stroke, or multi-infarct dementia, which is caused by multiple strokes in the brain can also induce dementia.
  • Alzheimer's disease accounts for approximately 50 to 70% of all dementias (See Koss E, et al., (1997), Assessing patterns of agitation in Alzheimer's disease patients with the Cohen- Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord ll(suppl 2):S45-S50). An estimated five percent of people aged 65 and older and up to 20 percent of those aged 80 and older are affected by dementia; of these sufferers, nearly half exhibit behavioral disturbances, such as agitation, wandering and violent outbursts.
  • Agitated behaviors can also be manifested in cognitively intact elderly people and by those with psychiatric disorders other than dementia.
  • the present invention provides methods for treating agitation in a patient in need of such treatment comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
  • the agitation is due to a psychiatric disorder other than dementia.
  • the present invention provides methods for treatment of agitation or a symptom thereof in a patient suffering from dementia comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein.
  • the dementia is due to a degenerative disease of the nervous system, for example and without limitation, Alzheimers disease, Lewy body, Parkinson's disease, and Huntington's disease, or dementia due to diseases that affect blood vessels, including, without limitation, stroke and multi-infarct dementia.
  • methods are provided for treating agitation or a symptom thereof in a patient in need of such treatment, where the patient is a cognitively intact elderly patient, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein. 4.
  • Schizophrenia is a psychopathic disorder of unknown origin, which usually appears for the first time in early adulthood and is marked by a number of characteristics, psychotic symptoms, progression, phasic development and deterioration in social behavior and professional capability in the region below the highest level ever attained.
  • Characteristic psychotic symptoms are disorders of thought content (multiple, fragmentary, incoherent, implausible or simply delusional contents or ideas of doctrine) and of mentality (loss of association, flight of imagination, incoherence up to incomprehensibility), as well as disorders of perceptibility (hallucinations), of emotions (superficial or inadequate emotions), of self-perception, of intentions and impulses, of interhuman relationships, and finally psychomotoric disorders (such as catatonia).
  • Haloperidol is a potent dopamine D 2 receptor antagonist. It is widely prescribed for acute schizophrenic symptoms, and is very effective for the positive symptoms of schizophrenia.
  • adding a 5-HT 2A inverse agonist concomitantly with Haldol will provide benefits including Hie ability to use a lower dose of Haldol without losing its effects on positive symptoms, while reducing or eliminating its inductive effects on negative symptoms, and prolonging relapse to the patient's next schizophrenic event.
  • the normal sleep cycle and sleep architecture can be disrupted by a variety of organic causes as well as environmental influences. According to the International Classification of Sleep Disorders, there are over 80 recognized sleep disorders. Of these, compounds of the present invention are effective, for example, in any one or more of the following sleep disorders (ICSD — International Classification of Sleep Disorders: Diagnostic and Coding Manual. Diagnostic Classification Steering Committee, American Sleep Disorders Association, 1990):
  • A. DYSSOMNIAS a. Intrinsic Sleep Disorders: Psychophysiological insomnia, Sleep state misperception, Idiopathic insomnia, Obstructive sleep apnea syndrome, Central sleep apnea syndrome, Central alveolar hypoventilation syndrome, Periodic limb movement disorder, Restless leg syndrome and Intrinsic sleep disorder NOS. b. Extrinsic Sleep Disorders:
  • Inadequate sleep hygiene Environmental sleep disorder, Altitude insomnia, Adjustment sleep disorder, Insufficient sleep syndrome, Limit-setting sleep disorder, SleepOnset association disorder, Nocturnal eating (drinking) syndrome, Hypnotic dependent sleep disorder, Stimulant- dependent sleep disorder, Alcohol-dependent sleep disorder, Toxin-induced sleep disorder and Extrinsic sleep disorder NOS.
  • Orcadian Rhythm Sleep Disorders Time zone change (jet lag) syndrome, Shift work sleep disorder, Irregular sleep-wake pattern, Delayed sleep phase syndrome, Advanced sleep phase syndrome, Non-24-hour sleep-wake disorder and Orcadian rhythm sleep disorder NOS.
  • Cerebral degenerative disorders Dementia, Parkinsonism, Fatal familial insomnia, Sleep- related epilepsy, Electrical status epilepticus of sleep and Sleep-related headaches, c. Associated with Other Medical Disorders:
  • benzodiazepines The most common class of medications for the majority of sleep disorders are the benzodiazepines, but the adverse effect profile of benzodiazepines include daytime sedation, diminished motor coordination, and cognitive impairments. Furthermore, the National Institutes of Health Consensus conference on Sleeping Pills and Insomnia in 1984 have developed guidelines discouraging the use of such sedative-hypnotics beyond 4-6 weeks because of concerns raised over drug misuse, dependency, withdrawal and rebound insomnia. Therefore, it is desirable to have a pharmacological agent for the treatment of insomnia, which is more effective and/or has fewer side effects than those currently used. In addition, benzodiazepines are used to induce sleep, but have little to no effect on the maintenance of sleep, sleep consolidation or slow wave sleep.
  • Some sleep disorders are sometimes found in conjunction with other conditions and accordingly those conditions are treatable by compounds of Formula (Ia).
  • patients suffering from mood disorders typically suffer from a sleep disorder that can be treatable by compounds of Formula (Ia).
  • Having one pharmacological agent which treats two or more existing or potential conditions, as does the present invention, is more cost effective, leads to better compliance and has fewer side effects than taking two or more agents.
  • Compounds of the present invention described herein may be used alone or in combination with a mild sleep inducer , such as, a sedating antihistamine (diphenhydramine, chloropheniramine, bromopheniramine and the like), GABA-A receptor modulators (Ambien, Sonata, Indiplon, Gaboxadol, and the like), melatonin agonists (MLl receptor agonist, such as Ramelteon and the like), sedating antidepressants (such as a tricyclic antidepressant, doxepine and the like), and benzodiazepines (diazepam and the like) and either administered together or separately.
  • a mild sleep inducer such as, a sedating antihistamine (diphen
  • NREM sleep comprises two physiological states: Non rapid eye movement (NREM) and rapid eye movement (REM) sleep.
  • NREM sleep consists of four stages, each of which is characterized by progressively slower brain wave patterns, with the slower patterns indicating deeper sleep. So called delta sleep, stages 3 and 4 of NREM sleep, is the deepest and most refreshing type of sleep. Many patients with sleep disorders are unable to adequately achieve the restorative sleep of stages 3 and 4. In clinical terms, patients' sleep patterns are described as fragmented, meaning the patient spends a lot of time alternating between stages 1 and 2 (semi- wakefulness) and being awake and very little time in deep sleep.
  • fragmented sleep architecture means an individual, such as a sleep disorder patient, spends the majority of their sleep time in NR-EM sleep stages 1 and 2, lighter periods of sleep from which the individual can be easily aroused to a waking state by limited external stimuli. As a result, the individual cycles through frequent bouts of light sleep interrupted by frequent awakenings throughout the sleep period. Many sleep disorders are characterized by a fragmented sleep architecture. For example, many elderly patients with sleep complaints have difficulty achieving long bouts of deep refreshing sleep (NREM stages 3 and 4) and instead spend the majority of their sleep time in NREM sleep stages 1 and 2.
  • the term “sleep consolidation” means a state in which the number of NREM sleep bouts, particularly Stages 3 and 4, and the length of those sleep bouts are increased, while the number and length of waking bouts are decreased.
  • the architecture of the sleep disorder patient is consolidated to a sleeping state with increased periods of sleep and fewer awakenings during the night and more time is spent in slow wave sleep (Stages 3 and 4) with fewer oscillation Stage 1 and 2 sleep.
  • Compounds of the present invention can be effective in consolidating sleep patterns so that the patient with previously fragmented sleep can now achieve restorative, delta-wave sleep for longer, more consistent periods of time.
  • NREM sleep makes up about 75% of total sleep time; stage 1 accounting for 5-10% of total sleep time, stage 2 for about 45-50%, stage 3 approximately 12%, and stage 4 13-15%. About 90 minutes after sleep onset, NREM sleep gives way to the first REM sleep episode of the night. REM makes up approximately 25% of total sleep time. Ih contrast to NREM sleep, REM sleep is characterized by high pulse, respiration, and blood pressure, as well as other physiological patterns similar to those seen in the active waking stage. Hence, REM sleep is also known as "paradoxical sleep.” Sleep onset occurs during NREM sleep and takes 10-20 minutes in healthy young adults.
  • the four stages of NREM sleep together with a REM phase form one complete sleep cycle that is repeated throughout the duration of sleep, usually four or five times.
  • the cyclical nature of sleep is regular and reliable; a REM period occurs about every 90 minutes during the night.
  • the first REM period tends to be the shortest, often lasting less than 10 minutes, whereas the later REM periods may last up to 40 minutes.
  • the time between retiring and sleep onset increases and the total amount of night-time sleep decreases because of changes in sleep architecture that impair sleep maintenance as well as sleep quality. Both NREM (particularly stages 3 and 4) and REM sleep are reduced.
  • stage 1 NREM sleep which is the lightest sleep, increases with age.
  • delta power means a measure of the duration of EEG activity in the 0.5 to 3.5 Hz range during NREM sleep and is thought to be a measure of deeper, more refreshing sleep.
  • Delta power is hypothesized to be a measure of a theoretical process called Process S and is thought to be inversely related to the amount of sleep an individual experiences during a given sleep period. Sleep is controlled by homeostatic mechanisms; therefore, the less one sleeps the greater the drive to sleep. It is believed that Process S builds throughout the wake period and is discharged most efficiently during delta power sleep. Delta power is a measure of the magnitude of Process S prior to the sleep period. The longer one stays awake, the greater Process S or drive to sleep and thus the greater the delta power during NREM sleep.
  • onset, duration or quality of sleep e.g. non-restorative or restorative sleep
  • One method is a subjective determination of the patient, e.g., do they feel drowsy or rested upon waking.
  • Other methods involve the observation of the patient by another during sleep, e.g., how long it takes the patient to fall asleep, how many times does the patient wake up during the night, how restless is the patient during sleep, etc.
  • Another method is to objectively measure the stages of sleep using polysomnography.
  • Polysomnography is the monitoring of multiple electrophysiological parameters during sleep and generally includes measurement of EEG activity, electroculographic activity and electromyographic activity, as well as other measurements.
  • stage 1 NRJEM sleep is a transition from wakefulness to sleep and occupies about 5% of time spent asleep in healthy adults.
  • Stage 2 NREM sleep which is characterized by specific EEG waveforms (sleep spindles and K complexes), occupies about 50% of time spent asleep.
  • Stages 3 and 4 NREM sleep are the deepest levels of sleep and occupy about 10-20% of sleep time. REM sleep, during which the majority of vivid dreams occur, occupies about 20-25% of total sleep.
  • NREM stages 3 and 4 tend to occur in the first one-third to one-half of the night and increase in duration in response to sleep deprivation.
  • REM sleep occurs cyclically through the night. Alternating with NREM sleep about every 80-100 minutes. REM sleep periods increase in duration toward the morning. Human sleep also varies characteristically across the life span. After relative stability with large amounts of slow-wave sleep in childhood and early adolescence, sleep continuity and depth deteriorate across the adult age range. This deterioration is reflected by increased wakefulness and stage 1 sleep and decreased stages 3 and 4 sleep.
  • the compounds of the invention can be useful for the treatment of the sleep disorders characterized by excessive daytime sleepiness such as narcolepsy.
  • Inverse agonists at the serotonin 5-HT 2A receptor improve the quality of sleep at nightime which can decrease excessive daytime sleepiness. Accordingly, another aspect of the present invention relates to the therapeutic use of compounds of the present invention for the treatment of Sleep Disorders.
  • Compounds of the present invention are potent inverse agonists at the serotonin 5-HT 2A receptor and can be effective in the treatment of Sleep Disorders by promoting one or more of the following: reducing the sleep onset latency period (measure of sleep induction), reducing the number of nighttime awakenings, and prolonging the amount of time in delta-wave sleep (measure of sleep quality enhancement and sleep consolidation) without effecting REM sleep.
  • compounds of the present invention can be effective either as a monotherapy or in combination with sleep inducing agents, for example but not limited to, antihistamines.
  • Diabetic-Related Pathologies Although hyperglycemia is the major cause for the pathogenesis of diabetic complications such as diabetic peripheral neuropathy (DPN), diabetic nephropathy (DN) and diabetic retinopathy (DR), increased plasma serotonin concentration in diabetic patients has also been implicated to play a role in disease progression (Pietraszek, M.H., et al. Thrombosis Res. 1992, 66(6), 765-74; and Andrzejewska-Buczko J, et al., Klin Oczna. 1996; 98(2), 101-4). Serotonin is believed to play a role in vasospasm and increased platelet aggregability. Improving microvascular blood flow is able to benefit diabetic complications.
  • DPN diabetic peripheral neuropathy
  • DN diabetic nephropathy
  • DR diabetic retinopathy
  • sarpogrelate was evaluated for the prevention of the development or progression of diabetic nephropathy (Takahashi, T., et al., Diabetes Res CHn Pract. 2002 Nov; 58(2): 123-9). In the trial of 24 months of treatment, sarpogrelate significantly Teduced urinary albumin excretion level.
  • Topical ocular administration of 5-HT2 receptor antagonists result in a decrease in intra ocular pressure (IOP) in monkeys (Chang et al., J. Ocul Pharmacol 1 :137-147 (1985)) and humans (Mastropasqua et al., Acta Ophthalmol Scand Suppl 224:24-25 (1997)) indicating utility for similar compounds such as 5-HT 2A inverse agonists in the treatment of ocular hypertension associated with glaucoma.
  • the 5-HT2 receptor antagonist ketanserin (Mastropasqua supra) and sarpogrelate Takenaka et al., Investig Ophthalmol Vis Sci 36:S734 (1995) have been shown to significantly lower IOP in glaucoma patients.
  • PML Progressive multifocal leukoencephalopathy
  • the causative agent is JC virus, a ubiquitous papovavirus that infects the majority of the population before adulthood and establishes a latent infection in the kidney. In immunocompromised hosts, the virus can reactivate and productively infect oligodendrocytes. This previously rare condition, until 1984 reported primarily in persons with underlying lymphoproliferative disorders, is now more common because it occurs in 4% of patients with AIDS. Patients usually present with relentlessly progressive focal neurologic defects, such as herniparesis or visual field deficits, or with alterations in mental status. On brain MRI, one or more white matter lesions are present; they are hyperintense on T2-weighted images and hypointense on Tl -weighted images.
  • JC virus enters cells by receptor-mediated clathrin-dependent endocytosis. Binding of JC virus to human glial cells (e.g., oligodendrocytes) induces an intracellular signal that is critical for entry and infection by a ligand-inducible clathrin-dependent mechanism [Querbes et al., J Virology (2004) 78:250-256]. Recently, 5-HT 2A was shown to be the receptor on human glial cells mediating infectious entry of JC virus by clathrin-dependent endocytosis [Elphick et al., Science (2004) 306:1380-1383]. 5-HT 2A antagonists, including ketanserin and ritanserin, inhibited JC virus infection of human glial cells. Ketanserin and ritanserin have inverse agonist activity at 5- HT 2A .
  • 5-HT 2A antagonists including inverse agonists have been contemplated to be useful in the treatment of PML [Elphick et al., Science (2004) 306:1380-1383].
  • Prophylactic treatment of HIV-infected patients with 5-HT 2A antagonists is envisioned to prevent the spread of JC virus to the central nervous system and the development of PML.
  • Aggressive therapeutic treatment of patients with PML is envisioned to reduce viral spread within the central nervous system and prevent additional episodes of demyelination.
  • methods are provided for treating progressive multifocal leukoencephalopathy in a patient in need of such treatment, comprising administering to the patient a composition comprising a 5-HT 2A inverse agonist disclosed herein. 9.
  • Ketanserin a 5-HT2A inverse agonist
  • Ketanserin a 5-HT2A inverse agonist
  • Mainserin a 5-HT2A inverse agonist, has been shown to prevent DOCA-salt induced hypertension in rats (see, Silva, A. Eur, J. Pharmacol. 518(2-3): 152-7 2005).
  • 5-HT2A inverse agonists are also effective for the treatment of pain.
  • Sarpogrelate has been observed to provide a significant analgesic effect both on thermal induced pain in rats after intraperitoneal administration and on inflammatory pain in rats after either intrathecal or intraperitoneal administration (see, Nishiyama, T. Eur. J. Pharmacol. 516:18-22 2005).
  • This same 5-HT2A inverse agonist in humans has been shown to be an effective treatment for lower back pain, leg pain and numbness associated with sciatica brought on by lumbar disc herniation (see, Kanayama, M. et al. J. Neurosurg: Spine 2:441-4462005).
  • One aspect of the present invention pertains to methods for modulating the activity of a 5-HT JA serotonin receptor by contacting the receptor with a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for the treatment of platelet aggregation in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for the treatment of an indication selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for reducing blood clot formation in an angioplasty or coronary bypass surgery individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for reducing blood clot formation in an individual suffering from atrial fibrillation, comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for the treatment of asthma in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for the treatment of a symptom of asthma in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • One aspect of the present invention pertains to methods for the treatment of agitation or a symptom thereof in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the individual is a cognitively intact elderly individual.
  • One aspect of the present invention pertains to methods for the treatment of agitation or a symptom thereof in an individual suffering from dementia comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the dementia is due to a degenerative disease of the nervous system.
  • the dementia is Alzheimers disease, Lewy body, Parkinson's disease or Huntington's disease.
  • the dementia is due to diseases that affect blood vessels.
  • the dementia is due to stroke or multi-infarct dementia.
  • One aspect of the present invention pertains to methods for the treatment of an individual suffering from at least one of the indications selected from the group consisting of behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia comprising administering to the individual in need thereof a therapeutically effective amount of a dopamine D 2 receptor antagonist and a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One aspect of the present invention pertains to methods for the treatment of an individual with infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies comprising administering to the individual in need thereof a therapeutically effective amount of a dopamine D 2 receptor antagonist and a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One aspect of the present invention pertains to methods for the treatment of schizophrenia in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a dopamine D 2 receptor antagonist and a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One aspect of the present invention pertains to methods for the treatment of alleviating negative symptoms of schizophrenia induced by the administration of haloperidol to an individual suffering from the schizophrenia, comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the haloperidol and the compound or pharmaceutical composition are administered in separate dosage forms.
  • the haloperidol and the compound or pharmaceutical composition are administered in a single dosage form.
  • One aspect of the present invention pertains to methods for the treatment of a sleep disorder in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the sleep disorder is a dyssomnia.
  • the dyssomnia is selected from the group consisting of psychophysiological insomnia, sleep state misperception, idiopathic insomnia, obstructive sleep apnea syndrome, central sleep apnea syndrome, central alveolar hypoventilation syndrome, periodic limb movement disorder, restless leg syndrome, inadequate sleep hygiene, environmental sleep disorder, altitude insomnia, adjustment sleep disorder, insufficient sleep syndrome, limit-setting sleep disorder, sleep-onset association disorder, nocturnal eating or drinking syndrome, hypnotic dependent sleep disorder, stimulant-dependent sleep disorder, alcohol-dependent sleep disorder, toxin-induced sleep disorder, time zone change (jet lag) syndrome, shift work sleep disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, and non-24-hour sleep- wake disorder.
  • the sleep disorder is a parasomnia.
  • the parasomnia is selected from the group consisting of confusional arousals, sleepwalking and sleep terrors, rhythmic movement disorder, sleep starts, sleep talking and nocturnal leg cramps.
  • the sleep disorder is characterized by excessive daytime sleepiness such as narcolepsy.
  • the sleep disorder is associated with a medical or psychiatric disorder.
  • the medical or psychiatric disorder is selected from the group consisting of psychoses, mood disorders, anxiety disorders, panic disorders, alcoholism, cerebral degenerative disorders, dementia, parkinsonism, fatal familial insomnia, sleep-related epilepsy, electrical status epilepticus of sleep, sleep-related headaches, sleeping sickness, nocturnal cardiac ischemia, chronic obstructive pulmonary disease, sleep-related asthma, sleep-related gastroesophageal reflux, peptic ulcer disease, fibrositis syndrome, osteoarthritis, rheumatoid arthritis, fibromyalgia and post-surgical sleep disorder.
  • One aspect of the present invention pertains to methods for the treatment of a diabetic- related disorder in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the diabetic-related disorder is diabetic peripheral neuropathy.
  • the diabetic-related disorder is diabetic nephropathy. In some embodiments, the diabetic-related disorder is diabetic retinopathy.
  • One aspect of the present invention pertains to methods for the treatment of glaucoma or other diseases of the eye with abnormal intraocular pressure.
  • One aspect of the present invention pertains to methods for the treatment of progressive multifocal leukoencephalopathy in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound according to any of the embodiments described herein or a pharmaceutical composition.
  • the individual in need thereof has a lymphoproliferative disorder.
  • the lymphoproliferative disorder is leukemia or lymphoma.
  • the leukemia or lymphoma is chronic lymphocytic leukemia, Hodgkin's disease, or the like.
  • the individual in need thereof has a myeloproliferative disorder.
  • the individual in need thereof has carcinomatosis.
  • the individual in need thereof has a granulomatous or inflammatory disease.
  • the granulomatous or inflammatory disease is tuberculosis or sarcoidosis.
  • the individual in need thereof is immunocompromised.
  • the immunocompromised individual has impaired cellular immunity.
  • the impaired cellular immunity comprises impaired T-cell immunity.
  • the individual in need thereof is infected with HIV.
  • the HIV-infected individual has a CD4+ cell count of ⁇ 200/mm 3 .
  • the HIV-infected individual has AIDS.
  • the HIV-infected individual has ADDS-related complex (ARC).
  • ARC is defined as the presence of two successive CD4+ cell counts below 200/mm 3 and at least two of the following signs or symptoms: oral hairy leukoplakia, recurrent oral candidiasis, weight loss of at least 2.5 kg or 10% of body weight within last six months, multidermatomal herpes zoster, temperature above 38.5°C for more than 14 consecutive days or more than 15 days in a 30-day period, or diarrhea with more than three liquid stools per day for at least 30 days [see, e.g., Yamada et al., Clin. Diagn. Virol. (1993) 1:245-256].
  • the individual in need thereof is undergoing immunosuppressive therapy.
  • the immunosuppressive therapy comprises administering an immunosuppressive agent [see, e.g., Mueller, Ann Thorac Surg (2004) 77:354-362; and Krieger and Emre, Pediatr Transplantation (2004) 8:594-599].
  • the immunosuppressive therapy comprises administering an immunosuppressive agent selected from the group consisting of: corticosteroids (for example, prednisone and the like), calcineurin inhibitors (for example, cyclosporine, tacrolimus, and the like), antiproliferative agents (for example, azathioprine, mycophenolate mofetil, sirolimus, everolimus, and the like), T-cell depleting agents (for example, OKT ® 3 monoclonal antibody (mAb), anti-CD3 immunotoxin
  • corticosteroids for example, prednisone and the like
  • calcineurin inhibitors for example, cyclosporine, tacrolimus, and the like
  • antiproliferative agents for example, azathioprine, mycophenolate mofetil, sirolimus, everolimus, and the like
  • T-cell depleting agents for example, OKT ® 3 monoclonal antibody (mAb), anti-CD3 immunotoxin
  • the immunosuppressive agent and said compound or pharmaceutical composition are administered in separate doseage forms.
  • the immunosuppressive agent and said compound or pharmaceutical composition are administered in separate doseage forms.
  • the individual in need thereof is undergoing immunosuppressive therapy after organ transplantation.
  • the organ is liver, kidney, lung, heart, or the like [see, e.g., Singh et al., Transplantation (2000) 69:467-472].
  • the individual in need thereof is undergoing treatment for a rheumatic disease.
  • the rheumatic disease is systemic lupus erythematosus or the like.
  • the compound or the pharmaceutical composition inhibits JC virus infection of human glial cells.
  • One aspect of the present invention encompasses processes for preparing a composition comprising admixing a compound according any embodiments described herein and a pharmaceutically acceptable carrier.
  • One aspect of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is platelet aggregation.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is a blood clot formation in an angioplasty or coronary bypass surgery individual.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is a blood clot formation in an individual suffering from atrial fibrillation.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is asthma.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is a symptom of asthma.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is agitation or a symptom thereof in an individual.
  • the individual is a cognitively intact elderly individual.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is agitation or a symptom thereof in an individual suffering from dementia.
  • the dementia is due to a degenerative disease of the nervous system.
  • the dementia is Alzheimers disease, Lewy body, Parkinson's disease, or Huntington's disease.
  • the dementia is due to diseases that affect blood vessels.
  • the dementia is due to stroke or multi-infract dementia.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder further comprising a dopamine D 2 receptor antagonist wherein the disorder is selected from the group consisting of a behavioral disorder, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2 A associated disorder further comprising a dopamine D 2 receptor antagonist wherein the disorder is infantile autism, Huntington's chorea, or nausea and vomiting from chemotherapy or chemotherapeutic antibodies.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder further comprising a dopamine D 2 receptor antagonist wherein the disorder is schizophrenia.
  • the dopamine D 2 receptor antagonist is haloperidol.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is a negative symptom or symptoms of schizophrenia induced by the administration of haloperidol.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the haloperidol and the compound or pharmaceutical composition are administered in separate dosage forms.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the haloperidol and the compound or pharmaceutical composition are administered in a single dosage form.
  • One embodiment of the present invention is the use of a compound for the production of a medicament for use in the treatment of a 5-HT 2A associated disorder wherein the disorder is progressive multifocal leukoencephalopathy.
  • One aspect of the present invention are compounds according to any of the embodiments described herein for use in a method of treatment of the human or animal body by therapy.
  • One aspect of the present invention are compounds according to any of the embodiments described herein for use in a method for the treatment of a 5-HT 2A associated disorder, as described herein, in the human or animal body by therapy.
  • One aspect of the present invention are compounds according to any of the embodiments described herein for use in a method for the treatment of a sleep disorder, as .described herein, in the human or animal body by therapy.
  • One aspect of the present invention are compounds according to any of the embodiments described herein for use in a method for the treatment of platelet aggregation in the human or animal body by therapy.
  • One aspect of the present invention are compounds according to any of the embodiments described herein for use in a method for the treatment of progressive multifocal leukoencephalopathy in the human or animal body by therapy.
  • a further aspect of the present invention pertains to pharmaceutical compositions comprising one or more compounds as described herein and one or more pharmaceutically acceptable carriers. Some embodiments pertain to pharmaceutical compositions comprising a compound of the present invention and a pharmaceutically acceptable carrier. Some embodiments of the present invention include a method of producing a pharmaceutical composition comprising admixing at least one compound according to any of the compound embodiments disclosed herein and a pharmaceutically acceptable carrier.
  • Formulations may be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if necessary, forming the resulting mixture into a desired shape.
  • Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups.
  • the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants may be added to the liquid preparations.
  • Parenteral dosage forms may be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.
  • a compound of the present invention can be formulated into pharmaceutical compositions using techniques well known to those in the art. Suitable pharmaceutically- acceptable carriers, outside those mentioned herein, are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20th Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro, A. R., et al.).
  • a compound of the invention may, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present the compound or active ingredient as a pharmaceutical formulation or composition further comprising a pharmaceutically acceptable carrier.
  • the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers thereof and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not overly deleterious to the recipient thereof.
  • Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with a minimum of degradation of the drug.
  • transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner.
  • the compounds of the invention may thus be placed into the form of pharmaceutical formulations and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
  • Examples of such dosage units are capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as com starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate.
  • the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable pharmaceutically acceptable carrier.
  • active ingredient is defined in the context of a
  • pharmaceutical composition and shall mean a component of a pharmaceutical composition that provides the primary pharmacological effect, as opposed to an "inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit.
  • the dose when using the compounds of the present invention can vary within wide limits, as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the patient, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention.
  • Representative doses of the present invention include, but are not limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to about 1000 mg, 0.001 mg to about 500 mg, 0.001 mg to about 250 mg, about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg, and about 0.001 mg to about 25 mg.
  • Multiple doses may be administered during the day, especially when relatively large amounts are deemed to be needed, for example 2, 3 or 4, doses. Depending on the individual and as deemed appropriate from the patient's physician or care-giver it may be necessary to deviate upward or downward from the doses described herein.
  • the amount of active ingredient, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
  • a model system typically an animal model
  • these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors.
  • Representative factors include the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, or whether an acute or chronic disease state is being treated or prophylaxis is conducted or on whether further active compounds are administered in addition to the compounds of the present invention and as part of a drug combination.
  • the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety factors as cited above.
  • the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this invention.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
  • the daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4, part administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
  • the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted to the desire shape and size.
  • the powders and tablets may contain varying percentage amounts of the active compound.
  • a representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active compound; however, an artisan would know when amounts outside of this range are necessary.
  • Suitable carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • preparation is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as an admixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions maybe formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile ⁇ injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of inj ectables .
  • the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-f ⁇ lled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the formulations may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
  • the compounds of the present invention or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
  • Pharmaceutical forms for administration of the compounds of the present invention as an aerosol can be prepared by processes well- known to the person skilled in the art.
  • solutions or dispersions of the compounds of the present invention in water, water/alcohol mixtures or suitable saline solutions can be employed using customary additives, for example benzyl alcohol or other suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants and others, and, if appropriate, customary propellants, for example include carbon dioxide, CFCs, such as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like.
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
  • the active ingredients may be provided in the form of a dry powder, for example, a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
  • the compounds according to the invention may optionally exist as pharmaceutically acceptable salts including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • Representative acids include, but are not limited to, acetic, benzenesulfonic, benzoic, camphoTsulfonic, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfiric, tartaric, oxalic, p-toluenesulfonic and the like, such as those pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977); incorporated herein by reference in its entirety.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • Pro-drugs refers to compounds that have been modified with specific chemical groups known in the art and when administered into an individual these groups undergo biotransformation to give the parent compound. Pro-drugs can thus be viewed as compounds of the invention containing one or more specialized non-toxic protective groups used in a transient manner to alter or to eliminate a property of the compound. In one general aspect, the "pro-drug” approach is utilized to facilitate oral absorption.
  • T. Higuchi and V. Stella "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B.
  • Some embodiments of the present invention include a method of producing a pharmaceutical composition for "combination-therapy" comprising admixing at least one compound according to any of the compound embodiments disclosed herein, together with at least one known pharmaceutical agent as described herein and a pharmaceutically acceptable carrier.
  • 5-HT 2A receptor modulators when utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non- human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of active agents, such as 5-HT 2A receptor modulators, for the treatment of a 5-HT 2A mediated disease or disorder in domestic animals ⁇ e.g., cats and dogs) and in other domestic animals (e.g., such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.
  • COMBINATION THERAPY While the compounds of the present invention can be administered as the sole active pharmaceutical agent (i.e., mono-therapy), they can also be used in combination with other pharmaceutical agents (i.e., combination-therapy) for the treatment of the diseases/conditions/disorders described herein. Accordingly, another aspect of the present invention includes methods of treatment of 5-HT 2A serotonin receptor associated disorders diseases comprising administering to an individual in need of such treatment a therapeutically- effective amount of a compound of the present invention in combination with one or more additional pharmaceutical agent as described herein.
  • Suitable pharmaceutical agents that can be used in combination with the compounds of the present invention include other antiplatelet, antithrombotic or anticoagulant drugs, anti- arrhythmic agents, Cholesteryl ester transfer protein (CETP) inhibitors, Niacin or niacin analogs, Adenosine or adenosine analogs, Nitroglycerin or nitrates, prothrombolytic agents, and the like.
  • Other pharmaceutical agents including the agents set forth infra, are well known or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.
  • the compounds of the present invention can also be used in combination with other antiplatelet, antithrombotic or anticoagulant drugs such as thrombin inhibitors, platelet aggregation inhibitors such as aspirin, clopidogrel (Plavix®), ticlopidine or CS-747 ⁇ i.e., acetic acid 5-[2-cyclopropyl-l-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2- yl ester and its active metabolite ⁇ -99224, (Z)-2-[l-[2-cyclopropyl-l(S)-(2-fluorophenyl)-2- oxoethyl]-4(i?)-sulfanylpiperidin-3-ylidene]acetic acid ⁇ , abciximab (ReoPro®), eptifibatide (Integrilin®), tirofiban (A
  • antihypertensive agents such as angiotensin-converting enzyme inhibitors (e.g., captopril, lisinopril or fosinopril); angiotensin-II receptor antagonists (e.g., irbesartan, losartan or valsartan); and/or ACE/NEP inhibitors (e.g., omapatrilat and gemopatrilat); ⁇ -blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with aspirin, ifetroban, picotamide, ketanserin, or clopidogrel (Plavix®) and the like.
  • angiotensin-converting enzyme inhibitors e.g., captopril, lisinopril or fosinopril
  • angiotensin-II receptor antagonists e.g., irbesartan, losartan or valsartan
  • the compound of the present invention can also be used in combination with antiarrhythmic agents such as for atrial fibrillation, for example, amiodarone or dofetilide.
  • antiarrhythmic agents such as for atrial fibrillation, for example, amiodarone or dofetilide.
  • the compound of the present invention can also be used in combination with Cholesteryl ester transfer protein (CETP) inhibitors for dislipidemia and atherosclerosis, Niacin or niacin analogs for dislipidemia and atherosclerosis, Adenosine or adenosine analogs for vasodilation, Nitroglycerin or nitrates for vasodilation.
  • CETP Cholesteryl ester transfer protein
  • the compounds of the present invention can be used in combination with prothrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prour ⁇ kmase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators, and the like.
  • tissue plasminogen activator natural or recombinant
  • streptokinase reteplase
  • activase lanoteplase
  • urokinase prour ⁇ kmase
  • ASPAC anisolated streptokinase plasminogen activator complex
  • animal salivary gland plasminogen activators and the like.
  • the compounds of the present invention may also be used in combination with ⁇ - adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, or fenoterol; anticholinergics such as ipratropium bromide; anti-inflammatory cortiocosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone, flunisolide or dexamethasone; and anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast.
  • ⁇ - adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, or fenoterol
  • anticholinergics such as ipratrop
  • Suitable pharmaceutical agents that can be used in combination with compounds of the present invention include antiretrovirals [see, e.g., Turpin, Expert Rev Anti Infect Ther (2003) 1 :97-128].
  • Some embodiments of the present invention include methods of treatment of progressive multifocal leukoencephalopathy as described herein comprising administering to an individual in need of such treatment a therapeutically effective amount or dose of a compound of the present invention in combination with at least one pharmaceutical agent selected from the group consisting of: nucleoside reverse transcriptase inhibitors (for example, Retrovir ® , Epivir ® , Combivir ® , Hivid ® , Videx ® , Trizvir ® , Zerit ® , Ziagen ® , Vired ® , Emtricitabine, DAPD, and the like), non-nucleoside reverse transcriptase inhibitors (for example, Virammune ® , Rescriptor ® , Sustiva ® , GW68
  • a compound of the invention can be used in conjunction with highly active antiretroviral therapy (HAART).
  • HAART highly active antiretroviral therapy
  • the combination of a compound of the present invention and pharmaceutical agent can be prepared by mixing the respective active components either all together or independently with a pharmaceutically acceptable carrier, excipient, binder, diluent, etc. as described herein, and administering the mixture or mixtures either orally or non- orally as a pharmaceutical composition(s).
  • compositions of the present invention comprise a compound or a mixture of compounds of Formula (Ia) and the pharmaceutical agent(s) as a single pharmaceutical composition.
  • Another object of the present invention relates to radio-labeled compounds of the present invention that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the 5-HT 2A receptor in tissue samples, including human, and for identifying 5-HT 2A receptor ligands by inhibition binding of a radio-labeled compound. It is a further object of this invention to develop novel 5-HT 2 A receptor assays of which comprise such radio-labeled compounds.
  • the present invention embraces isotopically-labeled compounds of the present invention.
  • An “isotopically” or “radio-labeled” compounds are those which are identical to compounds disclosed herein, but for the fact that one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include, but are not limited to, 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 O, 18 0, 18 F, 35 S 3 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 1, 124 I, ' 25 I and 131 I.
  • the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound.
  • a “radio-labeled " or “labeled compound” is a compound of Formula (Ia) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting Of 3 H, 14 C, 125 1 , 35 S and 82 Br. Certain isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. In some embodiments the radionuclide 3 H and/or 14 C isotopes are useful in these studies.
  • isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes supra and Examples infra, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Other synthetic methods that are useful are discussed infra. Moreover, it should be understood that all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the more scarce radio-isotope or nonradio-active isotope.
  • Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art. These synthetic methods, for example, incorporating activity levels of tritium into target molecules, are as follows:
  • Synthetic methods for incorporating activity levels of 125 I into target molecules include:
  • This method is generally a two step process.
  • the first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, a Pd catalyzed reaction [i.e. Pd(Ph 3 P) 4 ] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH 3 )3SnSn(CH 3 ) 3 ].
  • a tri-alkyltinhalide or hexaalkylditin e.g., (CH 3 )3SnSn(CH 3 ) 3 ].
  • a radio-labeled 5-HT 2A receptor compound of Formula (Ia) can be used in a screening assay to identify/evaluate compounds.
  • a newly synthesized or identified compound i.e., test compound
  • test compound can be evaluated for its ability to reduce binding of the "radio- labeled compound of Formula (Ia)" to the 5-HT 2A receptor. Accordingly, the ability of a test compound to compete with the "radio-labeled compound of Formula (Ia)" for the binding to the 5-HT 2A receptor directly correlates to its binding affinity.
  • the labeled compounds of the present invention bind to the 5-HT 2A receptor.
  • the labeled compound has an IC 50 less than about 500 ⁇ M, in another embodiment the labeled compound has an IC 50 less than about 100 ⁇ M, in yet another embodiment the labeled compound has an ICs 0 less than about 10 ⁇ M, in yet another embodiment the labeled compound has an IC 50 less than about 1 ⁇ M, and in still yet another embodiment the labeled inhibitor has an IC50 less than about 0.1 ⁇ M.
  • Other uses of the disclosed receptors and methods will become apparent to those in the art based upon, inter alia, a review of this disclosure.
  • EXAMPLE 1 Syntheses of compounds of the present invention. Illustrated syntheses for compounds of the present invention are shown in Figures 1 through 9 where the symbols have the same definitions as used throughout this disclosure.
  • TLC Thin-layer chromatography
  • PK6F silica gel 60 A 1 mm plates (Whatman)
  • column chromatography was carried out on a silica gel column using Kieselgel 60, 0.063-0.200 mm (Merck). Evaporation was done under reduced pressure on a Buchi rotary evaporator. Celite 545® was used during palladium filtrations.
  • LCMS specs 1) PC: HPLC-pumps: LC-IOAD VP, Shimadzu Inc.; HPLC system controller: SCL-IOA VP, Shimadzu Inc; UV-Detector: SPD-IOA VP, Shimadzu Inc;
  • UV-Detector SPD-IOA VP, Shimadzu Inc; Autosampler: 215 Liquid Handler, Gilson Inc; Mass spectrometer: API 150EX with Turbo Ion Spray source, AB/MDS Sciex Software: Masschrom 1.5.2.
  • Example 1.1 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yI)-4-(2-morpholin-4-yl- ethoxy)-phenyl]-2-phenoxy-acetamide (Compound B15). Chloroacetyl chloride (0.00876 mL, 0.110 mmol) was added to a solution of 3-(2- methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-aniline (30.2 mg, 0.100 mmol) in DMF (0.2 mL), and the mixture was stirred at 23 0 C.
  • 2-(2-Fluorophenoxy)acetic acid (12.8 mg, 75.0 ⁇ mol) was dissolved in a solution of HBTU (1 M in DMF) (0.0750 mL, 75.0 ⁇ mol) and N,N-diisopropylethylamine (0.0174 mL, 100.0 ⁇ mol), and the mixture was stirred at 23 0 C. After 15 minutes, a solution of 3-(l-methyl- lH-py ⁇ azol-5-yl)-4-(2-(pyrrolidin-l-yl)ethoxy)aniline (14.31 mg, 50.0 ⁇ mol) in DMF, (0.100 mL) was added, and the solution was stirred for 20 hours at room temperature.
  • Propylphoshonic anhydride (50% in ethyl acetate, 0.0688 mL, 117 ⁇ mol) was added to a solution of 2-(3-fluorophenoxy)acetic acid (13.2 mg, 77.9 ⁇ mol), 4-methoxy-3-(4-methoxy-2- methyl-2H-pyrazol-3-yl)aniline (0.085 mL, 38.9 ⁇ mol) and N,N-diisopropylethylamine (0.0678 mL, 389 ⁇ mol) in DMF (O.OS mL).
  • Example 1.6 Preparation of 2-(3-Fluoro-phenoxy)-N-[3-(2-methyl-2H-pyrazoI-3-yI)-4-(2- morpholin-4-yl-ethoxy)-phenyI]-acetamide (Compound B27).
  • Example 1.12 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl- ethoxy)-phenyl]-2-(4-trifluorom ⁇ thyI-phenoxy)-acetamide (Compound B80).
  • the title compound was prepared in a similar manner as described in Example 1.1 to give the TFA salt (51.6 mg, 83%).
  • LCMS m/z (%) 505.4 (M+H, 100%).
  • Example 1.17 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yI)-4-(2-morpholin-4-yl- ethoxy)-phenyl]-2-m-tolyloxy-acetamide (Compound BS8).
  • the title compound was prepared in a similar manner as described in Example 1.1 and converted into the free base (34.8 mg, 72%).
  • LCMS m/z (%) 451.2 (M+H, 100%).
  • Example 1.20 Preparation of 2-(2-Cyano-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-acetamide (Compound B22).
  • Example 1.22 Preparation of 2-(Benzo[l ⁇ ]dioxol-5-yloxy)-N-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-morphoIin-4-y_-ethoxy)-phenyl]-acetam ⁇ de (Compound B49).
  • Example 1.24 Preparation of 2-(4-Fluoro-phenoxy)-N-[3-(2-methyI-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-acetamide (Compound B82).
  • Example 1.25 Preparation of 2-(4-Chloro-phenoxy)-N-[3-(2-methyl-2H-pyrazoI-3-yl)-4- (2-pyrrolid ⁇ n-l-yl-ethoxy)-phenyl]-acetamide (Compound Bl 9). 4-Chlorophenoxy-acetylchloride (12.8 mg, 0.0625 mmol) was added to a solution of 3-
  • Example 1.26 Preparation 2-Chloro-N-(3-(2-methyI-2H-pyrazol-3-yl)-4-(2-(piperidin-l- yl)ethoxy)phenyl)acetamide.
  • Example 1.30 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-piperidin-l-yl- ethoxy)-phenyl]-2-(3-trifluoromethyl-phenoxy)-acetamide (Compound B75).
  • Example 1.31 Preparation of 2-(3-FIuoro-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2- piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound B81).
  • Example 1.33 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-piperidin-l-yl- ethoxy)-phenyl]-2-m-toIyloxy-acetamide (Compound B92).
  • Example 1.34 Preparation of 2-(3-Methoxy-phenoxy)-N-[3-(2-methyl-2H-pyrazoI-3-yl)-4- (2-piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound B98).
  • the title compound was prepared in a similar manner as described in Example 1.2. Yield (7.1 mg, 31%).
  • LCMS m/z (%) 465.2 (M+H, 100%).
  • Example 1.35 Preparation of 2-(4-Fluoro-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2- piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound Bl 06).
  • Example 1.36 Preparation of 2-(4-Chloro-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4- (2-piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound BlOl).
  • Example 1.37 Preparation of N-[3-(2-MethyI-2H-pyrazol-3-yl)-4-(2-piperidin-l-yl- ethoxy)-phenyl]-2-p-tolyloxy-acetamide (Compound B34).
  • Example 1.39 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-piperidin-l-yl- ethoxy)-phenyl]-2-(4-trifluoromethoxy-phenoxy)-acetamide (Compound B73).
  • the title compound was prepared in a similar manner as described in Example 1.2. Yield (8.1 mg, 31%).
  • LCMS m/z (%) 519.4 (M+H, 100%).
  • Example 1.40 Preparation of 2-(4-Cyano-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2- piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound BlO). The title compound was prepared in a similar manner as described in Example 1.2.
  • Example 1.41 Preparation of 2-(Benzo[l 5 3]dioxoI-5-yloxy)-N-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound B20). The title compound was prepared in a similar manner as described in Example 1.2.
  • Example 1.42 Preparation of 2-(2,4-Difluoro-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)- 4-(2-piperidin-l-yl-ethoxy)-phenyl]-acetamide (Compound Bill). The title compound was prepared in a similar manner as described in Example 1.2.
  • Example 1.47 Preparation of 2-Benzyloxy-N-l3-(2-methyl-2H-pyrazol-3-y ⁇ )-4-(2- pyrrolidin-l-yl-etboxy)-phenyl]-acetamide (Compound B5).
  • Example 1.49 Preparation of N-l3-(2-MethyI-2H-pyrazol-3-yI)-4-(2-pyrrolidin-l-yI- ethoxy)-phenyl]-2-(2-trifluoromethyl-phe ⁇ oxy)-acetamide (Compound B61).
  • Example 1.50 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yI- ethoxy)-phenyl]-2-o-tolyIoxy-acetamide (Compound B69).
  • Example 1.51 Preparation of 2-(2-Methoxy-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4- (2-pyrroIidin-l-yl-ethoxy)-phenyl]-acetamide (Compound B77).
  • the title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.52 Preparation of 2-(3-Fluoro-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2- pyrrolidin-l-yl-ethoxy)-phenyl]-acetamide (Compound B83). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.54 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-2-(3-trifluoromethyl-phe ⁇ oxy)-acetamide (Compound B99).
  • the title compound was prepared in a similar manner as described in Example 1.3. Yield (18.0 mg, 74%).
  • LCMS m/z (%) 489.2 (M+H, 100%).
  • Example 1.55 Preparation of N-I3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-2-m-tolyIoxy-acetamide (Compound B30). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.58 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-2-(4-trifluoromethyl-phenoxy) ⁇ acetamide (Compound B8).
  • Example 1.60 Preparation of 2-(4-Methoxy-phenoxy)-N-[3-(2-methyl-2H-pyrazol-3-yl)-4- (2-pyrrolidin-l-yl-ethoxy)-phenyl]-acetamide (Compound BIlO).
  • Example 1.61 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-2-(4-trifluoromethoxy-phenoxy)-acetamide (Compound B64).
  • Example 1.62 Preparation of 2-(4-AcetyI-phenoxy)-N-[3-(2-methyI-2H-pyrazol-3-yl)-4-(2- pyrrolidin-l-yl-etboxy)-phenyl]-acetamide (Compound B79). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.66 Preparation of 2-(4-Chloro-phenoxy)-2-methyl-N-[3-(2-methyl-2H-pyrazol- 3-yl)-4-(2-pyrrolidin-l-yl-ethoxy)-phenyl]-propionamide (Compound B91).
  • Example 1.67 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(2-chloro-phenoxy)-acetamide (Compound B97). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.69 Preparation of N-[4-[2-(4-Aceryl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-o-tolyloxy-acetamide (Compound B3).
  • Example 1.70 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazoI-3-yI)-phenyl]-2-(3-fluoro-phenoxy)-acetamide (Compound B7).
  • Example 1.71 Preparation of N-[4-[2-(4-AcetyI-p ⁇ perazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(3-chloro-phenoxy)-acetamide (Compound B14).
  • Example 1.72 Preparation of N-[4-[2-(4-AcetyI-piperazin-l-yl)-ethoxyJ-3-(2-methyI-2H- pyrazol-3-yI)-phenyl]-2-(3-trifluoromethyl-phenoxy)-acetamide (Compound B17).
  • Example 1.74 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(3-methoxy-phenoxy)-acetamide (Compound B109).
  • Example 1.75 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyr azol-3-yl)-phenyl] -2-(4-fluoro-phenoxy)-acetamide (Co mpound B32).
  • Example 1.77 Preparation of N-[4-l2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-p-tolyloxy-acetamide (Compound B52).
  • the title compound was prepared in a similar manner as described in Example 1.3. Yield (23.6 mg, 96%).
  • LCMS m/z (%) 492.2 (M+H, 100%).
  • Example 1.78 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(4-methoxy-phenoxy)-acetamide (Compound B62).
  • Example 1.79 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(4-trifluoromethoxy-phenoxy)-acetamide (Compound B26).
  • Example 1.80 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxyJ-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(benzo [1,3] dioxol-5-yloxy)-acetamide (Compound B40). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.81 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yI)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyl]-2-(2,4-difluoro-phenoxy)-acetam ⁇ de (Compound B60).
  • the title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.82 Preparation of 2-(4-Acetyl-phenoxy)-N-[4-[2-(4-acetyl-piperazin-l-yI)- ethoxy]-3-(2-methyl-2H-pyrazol-3-yl)-phenyl]-acetamide (Compound B76). The title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.83 Preparation of N-(3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-methyI-2- nitropropoxy)phenyl)acetamide.
  • Cesium carbonate (7.04 g, 21.6 mmol) was added to a solution of 2-methyl-2- nitropropyl methanesulfonate (2.39 g, 12.1 mmol) andN-(4-hydroxy-3-(2-methyl-2H-pyrazol-3- yl)phenyl)acetamide (2.00 g, 8.65 mmol) in DMA (15 mL), and the mixture was stirred at 160 0 C. After 2 hours the solvent was evaporated, and the residue was triturated with water.
  • Example 1.84 Preparation of N-[4-(2-Amino-2-methyl-propoxy)-3-(4-bromo-2-methyl- 2H-pyrazol-3-yl)-phenyI]-2-(4-chloro-phenoxy)-acetamide (Compound B48). 2-(4-Chlorophenoxy)acetyl chloride (11 mg, 0.06 mmol) was added to a solution of 3-
  • Example 1.86 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyl]-2-p-tolylsuIfanyI-acetamide (Compound ClO).
  • the title compound was prepared in a similar manner as described in Example 1.3. Yield (7.9 mg, 35%).
  • LCMS m/z (%) 451.2 (M+H, 100%).
  • Example 1.87 Preparation of 2-(4-Fluoro-ptaenylsmfanyl)-N-l3-(2-methyl-2H-pyrazol-3- yl)-4-(2-pyrrolidin-l-yl-ethoxy)-phenyl]-acetamide (Compound C2).
  • the title compound was prepared in a similar manner as described in Example 1.3.
  • Example 1.90 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(2-methyl-2H- pyrazol-3-yl)-phenyi]-2-(4-fluoro-phenylsulfanyl)-acetamide (Compound C8).
  • Example 1.92 Preparation of l-(2-(benzyloxy)-5-nitrophenyl)-2-methoxyethanone.
  • l-(2-(benzyloxy)phenyl)-2-methoxyethanone (2.68 g, 10.5 mmol) was dissolved in acetic anhydride (1.50 mL, 15.9 mmol) and the solution was cooled to -20 0 C.
  • Nitrating acid was prepared by adding fuming nitric acid (1.10 mL, 27.0 mmol) to a mixture of acetic anhydride (1.50 mL, 15.9 mmol) and acetic acid (1.50 mL, 26.2 mmol).
  • Example 1.93 l-(2-(benzyIoxy)-5-nitrophenyl)-3-(dimethylamino)-2-methoxyprop-2-en-l- one.
  • l-(2-(Benzyloxy)-5-nitrophenyl)-2-methoxyethanone (1.52 g, 5045 ⁇ mol) and N 5 N- dimethylformamide dimethyl acetal (1013 ⁇ L, 7567 ⁇ mol) in 10 mL of DMF were heated to 120 0 C for 1 hour in a microwave oven. The dark brown solution was evaporated to dryness, and the residue was dissolved in DCM and filtered over a short silica gel column using ethyl acetate:hexanes 1:1 as the eluent.
  • Example 1.95 4-amino-2-(4-methoxy-2-methyI-2H-pyrazoI-3-yl)phenol Palladium on carbon (15 mg, 141 ⁇ mol) was added to a solution of 3-(2-(benzyloxy)-5- nitrophenyl)-4-methoxy-2-methyl-2H-pyrazole (975 mg, 2873 ⁇ mol) in THF (6 mL), and the mixture was stirred under hydrogen. After 30 minutes, large amounts of the intermediate nitrophenol had precipitated, and the reaction flask was placed in a 40 0 C water bath.
  • Example 1.96 tert-Butyl 4-hydroxy-3-(4-methoxy-2-methyl-2H-pyrazol-3- yl)phenylcarbamate.
  • Di-tert-butyl dicarbonate (685 mg, 3141 ⁇ mol) was added to a solution of 4-amino-2-(4- methoxy-2-methyl-2H-pyrazol-3-yl)phenol (626 mg, 2855 ⁇ mol) in DMF (5 mL), and the mixture was stirred at 40 0 C. After 1 hour, the solvent was evaporated under reduced pressure, and the residue was taken up in ethyl acetate and washed with 1 M citric acid, water, and brine.
  • Example 1.97 tert-butyl 4-methoxy-3-(4-methoxy-2-methyl-2H-pyrazoI-3- yl)phenylcarb amate.
  • Example 1.99 Preparation of N-[4-Methoxy-3-(4-methoxy-2-methyl-2H-pyrazol-3-yl)- phenyI]-2-(3- ⁇ iethoxy-phenoxy)-acetamide (Compound Bl).
  • the title compound was prepared in a similar manner as described in Example 1.4. Yield (11.9 mg, 77%).
  • LCMS m/z (%) 398.2 (M+H, 100%).
  • Example 1.100 Preparation of 2-(4-Fluoro-phenoxy)-N-[4-methoxy-3-(4-methoxy-2- methyI-2H-pyrazoI-3-yl)-phenyI]-acetamide (Compound B6).
  • Example 1.102 Preparation of ⁇ [3-(4-Chloro-2-methyl-2H- ⁇ yrazol-3-yl)-4-methoxy- phe ⁇ ylcarbamoyl]-methy]sulfanyl ⁇ -acetic acid (Compound C3).
  • Example 1.103 Preparation of ⁇ [3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenylcarbamoyl]-metboxy ⁇ -acetic acid (Compound B94).
  • Example 1.105 Preparation of N-[4-Methoxy-3-(4-methoxy-2-methyl-2H-pyrazoI-3-yl)- phenyI]-N'-methyI-N'-phenyl-oxalamide (Compound A90).
  • Example 1.106 Preparation of N-[4-Methoxy-3-(4-methoxy-2-methyl-2H-pyrazol-3-yl)- pbenyl]-N'-(2-methoxy-phenyl)-oxalamide (Compound A93).
  • Example 1.109 Preparation of N-[3-(2-Methyl-2H-pyrazol-3-yl)-4-(2-pyrrolidin-l-yl- ethoxy)-phenyI]-2-phenyls ⁇ iIfanyl-acetaniide (Compound C6).
  • Example 1.110 Preparation of N-l3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2-morphoHn- 4-yI-ethoxy)-phenyl]-2-(4-chloro-phenoxy)-acetamide (Compound B28).
  • 3-(4-chloro-l -methyl-lH-pyrazol-5-yl)-4-(2- morpholinoethoxy)benzenarnine 0.03368 g, 0.100 mmol
  • EtOAc 4- chlorophenoxyacetyl chloride
  • Example 1.112 Preparation of N-l3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin- 4-yl-ethoxy)-phenyl]-2-(4-trifluoromethoxy-phenoxy)-acetamide (Compound B93).
  • the title compound was prepared in a similar manner as described in Example 1.1; purified by preparative HPLC/MS and appropriate fractions were tyophilized to give the TFA salt.
  • the TFA salt was dissolved in DCM (5 mL) and the solution was treated with MP- Carbonate resin (100 mg) and stirred for.15 minutes to scavenge the TFA. The mixture was filtered to remove the resin and the filtrate was concentrated under reduced pressure to give a waxy, white solid (15.2 mg, 30.3%).
  • LCMS m/z (%) 501 (M+H 35 Cl, 100), 503 (M+H 37 Cl, 30).
  • Example 1.114 Preparation of N-[3-(4-ChIoro-2-methyl-2H-pyrazol-3-yl)-4-(2-morphoJin- 4-yl-ethoxy)-phenyl]-2-hydroxy-acetamide (Compound BIOS).
  • the title compound was prepared (as a by-product from the synthesis of Example 1.113) in a similar manner as described in Example 1.1; purified by preparative HPLCVMS and appropriate fractions were lyophilized to give the TFA salt.
  • the TFA salt was dissolved in DCM (5 rnL) and the solution was treated with MP-Carbonate resin (100 mg) and stirred for 15 minutes to scavenge the TFA.
  • Example 1.117 Preparation of 2-BenzyIoxy-N-[3-(4-chloro-2-methyl-2H-pyrazol-3-yl)-4- (2-morpholin-4-yl-ethoxy)-phenyl]-acetamide (Compound Bl 6).
  • the title compound was prepared in a similar manner as described in Example 1.110 to give a waxy white solid (27.6 mg, 58.6%).
  • LCMS m/z (%) 485 (M+H 35 Cl, 100), 487 (M+H , 37 Cl, 30).
  • Example 1.125 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(4-chloro-2- methyl-2H-pyrazol-3-yl)-phenyl]-2-(benzo[l,3]dioxol-5-yloxy)-acetamide (Compound B78).
  • the title compound was prepared in a similar manner as described in Example 1.112 and purified by preparative HPLC to give a white solid (2.1 mg, 6.6%).
  • LCMS m/z (%) 556 (M+H 35 Cl, 100), 558 (M+H 37 Cl, 30).
  • 1 H NMR 400 MHz, CDCl 3 ) ⁇ ppm 2.07 (s, 3H), 2.29-
  • Example 1.126 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(4-chloro-2- methyl-2H-pyrazol-3-yl)-phenyI]-2-(2,4-difluoro-phenoxy)-acetamide (Compound B84).
  • the title compound was prepared in a similar manner as described in Example 1.112 and purified by preparative HPLC to give a white solid (8.0 mg, 25.3%).
  • LCMS m/z (%) 548 (M+H 35 Cl, 100), 550 (M+H 37 Cl, 30).
  • Example 1.127 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(4-chloro-2- methyl-2H-pyrazol-3-yl)-phenyI]-2-m-toIyloxy-acetamide (Compound BS8).
  • Example 1.128 Preparation of N-[4-[2-(4-Acetyl-piperazin-l-yl)-ethoxy]-3-(4-chloro-2- methyI-2H-pyrazol-3-yI)-phenyl]-2-(3-methoxy-phenoxy)-acetamide (Compound B95).
  • Example 1.129 Preparation of 2-(Benzo[l ⁇ ]dioxol-5-yloxy)-N-[3-(2,4-dimethyI-2H- pyrazol-3-yl)-4-(2-morphoIin-4-yI-ethoxy)-phenyl]-acetamide (Compound B96).
  • Example 1.130 Preparation of 2-(2,4-Difiuoro-phenoxy)-N-[3-(2,4-dimethyl-2H-pyrazol- 3-yl)-4-(2-morpholin-4-yl-ethoxy)-plienyl]-acetamide (Compound B29).
  • Example 1.131 Preparation of N-[3-(2,4-DimethyI-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl- ethoxy)-phenyl]-2-m-tolyloxy-acetamide (Compound B56).
  • the title compound was prepared in a similar manner as described in Example 1.112 and purified by preparative HPLC/MS; the appropriate fractions were pooled and lyophilized to give the TFA salt.
  • the TFA salt was dissolved in DCM (5 mL) and the solution was treated with MP-Carbonate resin (100 mg) and stirred for 15 minutes to scavenge the TFA. The mixture was filtered to remove the resin and the filtrate was concentrated under reduced pressure to give a white solid (25.0 mg, 54.6%).
  • LCMS m/z (%) 519 (M+H 35 Cl, 100), 521 (M+H 37 Cl, 50).
  • Example 1.135 Preparation of N-[3-(4-ChIoro-2-methyl-2H-pyrazoI-3-yl)-4-(2-morpholin- 4-yl-ethoxy)-phenyl]-2-(3,4-dimethoxy-phenylsuIfanyl)-acetamide (Compound Cl).
  • Example 1.137 Preparation of N-l3-(4-Chloro-2-methyl-2H-pyrazol-3-yI)-4-(2-morpholin- 4-yl-ethoxy)-phenyl]-N'-phenyl-oxaIamide (Compound A53). To a solution of 2-oxo-2-(phenylamino)acetic acid and N,N-diisopropylethylamine
  • Example 1.138 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyI]-2-(4-phenyl-piperazin-l-yl)-acetainide (Compound A33).
  • Example 1.139 Preparation of N-[3-(4-Bromo-2-methyl-2B-pyrazol-3-yl)-4-methoxy- phenyI]-2-cyclopropylamino-acetamide (Compound A37).
  • Example 1.140 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-fluoro-phenylamino)-acetamide (Compound A54).
  • Example 1.141 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yI)-4-methoxy- phenyl]-2-(3-methoxy-phenylamino)-acetamide (Compound A5).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a yellow solid (54%).
  • LCMS m/z (%) 445 (M+H 79 Br, 100), 447 (M+H 81 Br, 99).
  • Example 1.142 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl>4-methoxy- phenyl]-2-(4-fluoro-benzyIamino)-acetamide (Compound A13).
  • Example 1.143 Preparation of N-l3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phe ⁇ yl]-2-(3,5-difluoro-benzyIami ⁇ o)-aceta ⁇ iide (Compound A71).
  • Example 1.144 Preparation of N-[3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(3-methoxy-benzylamino)-acetamide (Compound A81).
  • Example 1.146 Preparation of N-l3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- pheny.]-2-[2-(4-fluoro-phenyl)-ethylaminoJ-acetamide (Compound A40).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (7%).
  • LCMS m/z (%) 461 (M+H 79 Br, 96), 463 (M+H 81 Br, 100).
  • Example 1.147 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[2-(3-methoxy-phenyl)-ethylamino)-acetamide (Compound A47).
  • Example 1.148 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-piperidin-l-yl-acetamide (Compound A58).
  • Example 1.150 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yI)-4-methoxy- pbenyl]-2-(4-fluoro-benzylatnino)-acetamide (Compound A56).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (33%).
  • LCMS m/z (%) 429 (M+H 79 Br, 100), 431 (M+H 81 Br, 98).
  • Example 1.151 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[4-(2-fluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A3).
  • Example 1.152 Preparation of N-[3-(4-Brom ⁇ -2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyI]-2-[4-(3-fluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A86).
  • Example 1.154 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[4-(4-chloro-phenyl)-piperazin-l-yl]-acetamide (Compound A38).
  • Example 1.156 Preparation of N-[3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(2-fluoro-benzylamino)-acetamide (Compound A55).
  • Example 1.157 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-methoxy-benzylamino)-acetamide (Compound A65).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (44%).
  • LCMS m/z (%) 459 (M+H 79 Br, 94), 461 (M+H 81 Br; 100).
  • Example 1.158 Preparation of N-[3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(2-methoxy-benzylamino)-acetamide (Compound A69).
  • Example 1.159 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[2-(4-fluoro-phenyl)-ethylamino]-acetamide (Compound A76).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (35%).
  • LCMS m/z (%) 461 (M+H 79 Br, 61), 463 (M+H 81 Br 3 100).
  • Example 1.160 Preparation of N-[3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[2-(2-fiuoro-phenyl)-ethylamino]-acetamide (Compound A21).
  • Example 1.161 Preparation of N-[3-(4-ChIoro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-fhioro-benzylamino)-acetamide (Compound A4).
  • Example 1.162 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- pheny]]-2-(3-fluoro-benzylamino)-acetamide (Compound AlO).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (22%).
  • LCMS m/z (%) 403 (M+H 35 Cl, 100), 405 (M+H 37 Cl, 38).
  • Example 1.166 Preparation of N-I3-(4-ChIoro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phe ⁇ yl]-2-[4-(3-fluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A61).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (55%).
  • LCMS m/z (%) 502 (M+H 35 Cl, 100), 504 (M+H 37 Cl, 43).
  • Example 1.168 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-phenyl-piperazin-l-yl)-acetamide (Compound A79).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (75%).
  • LCMS m/z (%) 440 (M+H 3S C1, 100), 442 (M+H 37 Cl, 42).
  • Example 1.169 Preparation of N-l3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[4-(4-chloro-phenyl)-piperazin-l-yl]-acetam ⁇ de (Compound A25).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a white solid (56%).
  • LCMS m/z (%) 474 (M+H 35 Cl 35 Cl, 100), 476 (M+H 35 Cl 37 Cl, 77), 478 (M+H 37 Cl 37 Cl, 16).
  • Example 1.170 Preparation of N-[3-(4-ChIoro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyI]-2-[4-(4-fluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A12).
  • Example 1.171 Preparation of 2-(4-Fluoro-phenylamino)-N-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-morpholm-4-yl-ethoxy)-phenyl]-acetamide (Compound Al 6).
  • Example 1.172 Preparation of 2-(2,4-Difluoro-phenylamino)-N-[3-(2-methyl-2H-pyrazol- 3-yl)-4-(2-morphoIin-4-yl-ethoxy)-phenyl]-acetamide (Compound A20).
  • Example 1.173 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazoI-3-yl)-4-methoxy- phenyl]-2-[4-(4-methoxy-phenyl)-piperazin-l-yl]-acetamide (Compound A57).
  • Example 1.174 Preparation of N-[3-(4-Chloro-2-methyI-2H-pyrazoI-3-yl)-4-methoxy- phenyl]-2-[4-(3-methoxy-phenyl)-piperazin-l-yl]-acetamide (Compound A63).
  • Example 1.175 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[4-(2,4-difluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A66).
  • Example 1.176 Preparation of N-t3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-pyr ⁇ din-2-yl-piperazin-l-yl)-acetamide (Compound A70).
  • Example 1.178 Preparation of 2-(4-Chloro-phenylamino)-N-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-morpholin-4-yI-ethoxy)-phenyl]-acetamide (Compound A80).
  • the title compound was prepared in a similar manner as described in Example 1.171 to afford the TFA salt as a pale solid (39%).
  • LCMS m/z (%) 470 (M+H 35 Cl, 100), 472 (M+H 37 Cl, 39).
  • Example 1.180 Preparation of 2-(3-Fluoro-phenylamino)-]S-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-morphoIin-4-yl-ethoxy)-phenyl]-acetamide (Compound A83).
  • the title compound was prepared in a similar manner as described in Example 1.171 to afford the TFA salt as a pale solid (15%).
  • LCMS m/z (%) 454 (M+H , 100).
  • Example 1.181 Preparation of 2-(2-Fluoro-phenylamino)-N-[3-(2-methyl-2H-pyrazol-3- yl)-4-(2-morphoUn-4-yl-ethoxy)-phenyl]-acetamide (Compound A32).
  • the title compound was prepared in a similar manner as described in Example 1.171 to afford the TFA salt as a pale solid (14%).
  • LCMS m/z (%) 454 (M+H , 100).
  • Example 1.182 Preparation of 2-(4-Chloro-2-fluoro-phenylamino)-N-[3-(2-methyl-2H- pyrazol-3-yl)-4-(2-morpholin-4-y.-ethoxy)-phenyl]-acetamide (Compound A48).
  • Example 1.184 Preparation of 2-(3,5-Difluoro-phenylamino)-N-I3-(2-methyl-2H-pyrazol- 3-yl)-4-(2-morpholin-4-yI-ethoxy)-phenyl]-acetamide (Compound A9).
  • the title compound was prepared in a similar manner as described in Example 1.171 to afford the TFA salt as a pale solid (12%).
  • LCMS m/z (%) 472 (M+H , 100).
  • Example 1.185 Preparation of 2-(2,5-Difluoro-phenylamino)-N-[3-(2-methyl-2H-pyrazol- 3-yl)-4-(2-morphoIin-4-yI-ethoxy)-phenyl]-acetamide (Compound A42).
  • the title compound was prepared in a similar manner as described in Example 1.171 to afford the TFA salt as a yellow solid (7%).
  • LCMS m/z (%) 472 (M+H , 100).
  • Example 1.186 Preparation of 2-[(4-Fluoro-phenyI)-methyl-amino]-N-[3-(2-methyI-2H- pyrazol-3-yl)-4-(2-morpholi ⁇ -4-yl-ethoxy)-phenyI]-acetamide (Compound A59).
  • Example 1.188 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyI]-2-[4-(3,4-d ⁇ fluoro-phenyl)-piperazin-l-yl]-acetamide (Compound A78).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a pale solid (55%).
  • LCMS m/z (%) 476 (M+H 35 Cl, 100), 478 (M+H 37 Cl, 47).
  • Example 1.189 Preparation of N-P-(4-Chloro-2-metnyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-p-tolyl-piperazin-l-yl)-acetamide (Compound A23).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a pale solid (32%).
  • LCMS m/z (%) 454 (M+H 35 Cl, 100), 456 (M+H 37 Cl, 53).
  • Example 1.190 Preparation of N-[3-(4-Chloro-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phe ⁇ yI]-2-(4-m-tolyl-piperazin-l-yl)-acetamide (Compound A36).
  • Example 1.192 Preparation of N-I3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(4-o-tolyl-piperazin-l-yl)-acetamide (Compound A52).
  • the title compound was prepared in a similar manner as described in Example 1.138 to afford the TFA salt as a pale solid (75%).
  • LCMS m/z (%) 454 (M+H 35 Cl, 100), 456 (M+H 37 Cl, 61).
  • Example 1.193 Preparation of N-l3-(4-Ctaloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyI]-2-[4-(2-cyano-phenyI)-piperazin-l-yl]-acetamide (Compound A22).
  • the title compound was prepared in a simila ⁇ manner as described in Example 1.138 to afford a yellow solid (20%).
  • LCMS m/z (%) 465 (M+H 35 Cl, 100), 467 (M+H 37 Cl, 48).
  • Example 1.194 Preparation of N-[3-(4-ChIoro-2-methyI-2H-pyrazol-3-yI)-4-methoxy- phenyl]-2-(4-thiazol-2-yl-piperazin-l-yl)-acetamide (Compound A29).
  • Example 1.195 Preparation of 2-[4-(4-Chloro-2-fluoro-phenyl)-piperazin-l-yI]-N-[3-(4- chIoro-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-acetamide (Compound A41).
  • Example 1.200 Preparation of N-[3-(4-Bromo-2-methyI-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-tert-butoxy-acetamide (Compound B36).
  • LCMS m/z 396.1 (M+H).
  • Example 1.201 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazoI-3-yl)-4-methoxy- phenyl]-2-ethoxy-acetamide (Compound B13).
  • Example 1.202 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-2-(4-chloro-phenylamino)-acetam ⁇ de (Compound A85).
  • Example 1.203 Preparation of N-[3-(4-Chloro-2-methyI-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-2-(3-methoxy-phenylamino)-acetamide (Compound A64).
  • Example 1.204 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yI)-4-(2- morpholin-4-yI-ethoxy)-phenyl]-2-(4-fluoro-phenylamino)-acetamide (Compound A73).
  • Example 1.205 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2- mor ⁇ holin-4-yl-ethoxy)-pheny]]-2-(4-methoxy-phenyIamino)-acetamide (Compound A31).
  • Example 1.206 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2- mor ⁇ holin-4-yI-ethoxy)-phenyl]-2-phenyIamino-acetarnide (Compound A15).
  • Example 1.208 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-2-(2-fluoro-phenylamino)-acetamide (Compound A88).
  • Example 1.209 Preparation of N-[3-(4-ChIoro-2-methyl-2H-pyrazol-3-yl)-4-(2- morpholin-4-yl-ethoxy)-phenyl]-2-cydopropyIamino-acetamide (Compound A34).
  • Example 1.210 Preparation of N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2- ⁇ 4-[2-(4-fluoro-phenyl)-ethyl]-piperazin-l-yl ⁇ -acetamide (Compound A82).
  • Example 1.211 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-(3,5-difluoro-benzylamino)-acetamide (Compound A8).
  • Example 1.212 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yI)-4-methoxy- phenyl]-2-(2,4-difluoro-benzylamino)-acetamide (Compound A14). To a solution of 3-(4-chloro-l-methyl-lH-pyrazol-5-yl)-4-methoxybenzenamine (0.070 g, 294.5 ⁇ mol) in DMA (2 mL) was added bromoacetyl bromide (27.02 ⁇ L, 309.2 ⁇ mol) and the mixture was stirred at room temperature for 30 minutes.
  • Example 1.213 Preparation of N-[3-(4-ChIoro-2-methyI-2H-pyrazol-3-yI)-4-methoxy- phenyl]-2-[(pyridin-3-ylmethyl)-aminol-acetamide (Compound A62).
  • Example 1.216 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazol-3-yl)-4-methoxy- phenyl]-2-[(pyridin-2-ylmethyl)-amino]-aceta ⁇ iide (Compound A72).
  • Example 1.217 Preparation of 2-(2,4-Difluoro-phenylamino)-N-[4-methoxy-3-(2-methyI- 2H-pyrazo--3-yl)-phenyl]-acetamide (Compound A87).
  • To a solution of 4-methoxy-3-(l-methyl-lH-pyrazol-5-yl)benzenamine (0.060 g, 295.2 ⁇ mol) in DMA (2 mL) was added bromoacetyl bromide (25.80 ⁇ L, 295.2 ⁇ mol) and the mixture was stirred at room temperature for 30 minutes.
  • Example 1.218 Preparation of 2-[4-(4-Fluoro-phenyI)-piperazin-l-yl]-N-[4-methoxy-3-(2- methyl-2H-pyrazol-3-yl)-phenyl]-acetamide (Compound A30).
  • Example 1.220 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazoI-3-yl)-4-methoxy- phenyl]-2-[4-(4-fluoro-benzyl)-piperazin-l-yl]-acetamide (Compound A46).
  • Example 1.224 Preparation of N-[3-(4-Chloro-2-methyl-2H-pyrazoI-3-yl)-4-methoxy- phenyl]-2- ⁇ 4-[2-(4-fluoro-phen.yl)-ethyl]-piperazin-l-yl ⁇ -aceta ⁇ iide (Compound Al).
  • Example 1.226 N-(3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl)-2- ( ⁇ ietl ⁇ ylantino)acetaniide (Compund A60).
  • the vector utilized be pCMV. This vector was deposited with the American Type Culture Collection (ATCC) on October 13, 1998 (10801 University Boulevard., Manassas, VA 20110-2209 USA) under the provisions of the Budapest Treaty for the International Recognition of the

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne certains composés représentés par la formule (1a) ainsi que des compositions pharmaceutiques les contenant, lesquels modulent l'activité du récepteur de la sérotonine 5-HT2A. Les composés et les compositions pharmaceutiques susmentionnés sont destinés à des méthodes utiles pour traiter l'agrégation plaquettaire, la coronaropathie, l'infarctus du myocarde, l'accident ischémique transitoire, l'angine, l'accident vasculaire cérébral, la fibrillation auriculaire, la coagulation sanguine, l'asthme ou l'un de ses symptômes, l'agitation ou l'un de ses symptômes, les troubles du comportement, la psychose induite par les médicaments, la psychose avec excitation, le syndrôme de Tourette, le trouble maniaque, la psychose organique ou non spécifiée, le trouble psychotique, la psychose, la schizophrénie aigue, la schizophrénie chronique, la schizophrénie non spécifiée, et les troubles apparentés, les troubles du sommeil, les troubles liés au diabète, la leucoencéphalopathie multifocale progressive et les troubles similaires. Cette invention concerne également des méthodes utiles pour le traitement de troubles associés au récepteur de la sérotonine 5-HT2A conjointement avec d'autres agents pharmaceutiques administrés séparément ou ensemble.
EP07809149A 2006-05-18 2007-05-17 Dérivés d'acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur Withdrawn EP2051978A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80180006P 2006-05-18 2006-05-18
PCT/US2007/012230 WO2007136875A2 (fr) 2006-05-18 2007-05-17 Dérivés d'acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur

Publications (1)

Publication Number Publication Date
EP2051978A2 true EP2051978A2 (fr) 2009-04-29

Family

ID=38723918

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07809149A Withdrawn EP2051978A2 (fr) 2006-05-18 2007-05-17 Dérivés d'acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur

Country Status (3)

Country Link
EP (1) EP2051978A2 (fr)
JP (1) JP2009537556A (fr)
WO (1) WO2007136875A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
CA2646076C (fr) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, amines secondaires et leurs derives utilises en tant que modulateurs des recepteurs 5-ht2a de la serotonine et utiles pour traiter les troubles lies a ces recepteurs
WO2007136689A2 (fr) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Formes cristallines et procédés de préparation de phénylpyrazoles utiles en tant que modulateurs des récepteurs 5-ht2a de la sérotonine
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
EP2190844B3 (fr) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Dérivés d'imidazo[1,2-a]pyridine utilisés comme modulateurs du récepteur sérotoninergique 5-ht2a dans le traitement des troubles qui lui sont associés
WO2009123714A2 (fr) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
WO2011075596A1 (fr) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Formes cristallines de certains dérivés de 3-phényl-pyrazole, modulatrices du récepteur 5-ht2a de la sérotonine, utiles pour le traitement de troubles y étant associés
AU2011280235A1 (en) * 2010-07-19 2013-03-07 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (fr) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
KR102209441B1 (ko) * 2015-09-04 2021-01-29 신풍제약주식회사 혈소판 응집 저해 효과를 갖는 화합물 및 그 염, 그리고 이를 포함하는 혈전성 질환 예방 또는 치료용 조성물
CN120359211A (zh) 2022-12-08 2025-07-22 盐野义制药株式会社 具有血清素受体结合活性的含氮杂环和碳环衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) * 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007136875A2 *

Also Published As

Publication number Publication date
JP2009537556A (ja) 2009-10-29
WO2007136875A3 (fr) 2008-04-10
WO2007136875A2 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
US10781180B2 (en) 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
AU2007254244B2 (en) 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2051978A2 (fr) Dérivés d&#39;acétamides utilisés en tant que modulateurs du récepteur de la sérotonine 5-ht2a utilisés pour le traitement de troubles associés à ce récepteur
WO2007120600A2 (fr) Dérivés de 3-pyridinylpyrazole comme modulateurs du récepteur 5-ht2a de la sérotonine utiles pour le traitement de troubles liés à ce dernier
EP2066641A1 (fr) Dérivés de pyrazole en tant que modulateurs du récepteur 5ht2a de la sérotonine utiles dans le traitement de troubles liés à ce récepteur
US20080015223A1 (en) Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
HK1263026A1 (en) Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
HK1102818B (en) 3-phenyl-pyrazole derivatives as modulators of the 5-ht-2a serotonin receptor useful for the treatment of disorders related thereto
HK1118552A (en) 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080327

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090420